AU2004270713A1 - Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands - Google Patents
Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands Download PDFInfo
- Publication number
- AU2004270713A1 AU2004270713A1 AU2004270713A AU2004270713A AU2004270713A1 AU 2004270713 A1 AU2004270713 A1 AU 2004270713A1 AU 2004270713 A AU2004270713 A AU 2004270713A AU 2004270713 A AU2004270713 A AU 2004270713A AU 2004270713 A1 AU2004270713 A1 AU 2004270713A1
- Authority
- AU
- Australia
- Prior art keywords
- pyridin
- pyrrolo
- alkyl
- methoxy
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000001072 heteroaryl group Chemical group 0.000 title claims description 44
- 108091005471 CRHR1 Proteins 0.000 title claims description 10
- 150000003230 pyrimidines Chemical class 0.000 title description 5
- 239000003446 ligand Substances 0.000 title description 2
- 150000003216 pyrazines Chemical class 0.000 title 1
- 150000003222 pyridines Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims description 246
- -1 tri-substituted, 1- naphthyl Chemical group 0.000 claims description 237
- 239000000203 mixture Substances 0.000 claims description 224
- 150000001875 compounds Chemical class 0.000 claims description 212
- 229910052736 halogen Inorganic materials 0.000 claims description 140
- 150000002367 halogens Chemical class 0.000 claims description 140
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 130
- 125000005843 halogen group Chemical group 0.000 claims description 111
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 105
- 229910052739 hydrogen Inorganic materials 0.000 claims description 98
- 239000001257 hydrogen Substances 0.000 claims description 98
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 90
- 150000003839 salts Chemical class 0.000 claims description 88
- 150000002431 hydrogen Chemical class 0.000 claims description 76
- 125000001424 substituent group Chemical group 0.000 claims description 75
- 229910052760 oxygen Inorganic materials 0.000 claims description 69
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 66
- 125000003545 alkoxy group Chemical group 0.000 claims description 64
- 125000003282 alkyl amino group Chemical group 0.000 claims description 54
- 229910052757 nitrogen Inorganic materials 0.000 claims description 54
- 125000004432 carbon atom Chemical group C* 0.000 claims description 53
- 150000003462 sulfoxides Chemical class 0.000 claims description 53
- 229910052717 sulfur Inorganic materials 0.000 claims description 53
- 108010056643 Corticotropin-Releasing Hormone Receptors Proteins 0.000 claims description 52
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 47
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 46
- 125000004043 oxo group Chemical group O=* 0.000 claims description 44
- 125000005842 heteroatom Chemical group 0.000 claims description 40
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 40
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 34
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 33
- 239000001301 oxygen Substances 0.000 claims description 31
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 29
- 125000000623 heterocyclic group Chemical group 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 28
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
- 125000004076 pyridyl group Chemical group 0.000 claims description 27
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 27
- 125000003118 aryl group Chemical group 0.000 claims description 26
- 125000001188 haloalkyl group Chemical group 0.000 claims description 26
- 229920006395 saturated elastomer Polymers 0.000 claims description 26
- 229910052799 carbon Inorganic materials 0.000 claims description 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 22
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 21
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 21
- 230000027455 binding Effects 0.000 claims description 21
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 19
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 19
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 19
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 18
- 239000011593 sulfur Substances 0.000 claims description 18
- 125000001544 thienyl group Chemical group 0.000 claims description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 16
- 125000004122 cyclic group Chemical group 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 238000000338 in vitro Methods 0.000 claims description 16
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 16
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 15
- 125000002541 furyl group Chemical group 0.000 claims description 15
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 125000002971 oxazolyl group Chemical group 0.000 claims description 15
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 15
- 239000000523 sample Substances 0.000 claims description 15
- 125000000335 thiazolyl group Chemical group 0.000 claims description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 14
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 125000001425 triazolyl group Chemical group 0.000 claims description 13
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 12
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 11
- 208000019901 Anxiety disease Diseases 0.000 claims description 10
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 10
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 10
- 125000002757 morpholinyl group Chemical group 0.000 claims description 10
- 125000004193 piperazinyl group Chemical group 0.000 claims description 10
- 125000003386 piperidinyl group Chemical group 0.000 claims description 10
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 10
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 9
- 125000005605 benzo group Chemical group 0.000 claims description 9
- 238000001525 receptor binding assay Methods 0.000 claims description 9
- 150000003457 sulfones Chemical class 0.000 claims description 9
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 8
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 8
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 8
- 125000004414 alkyl thio group Chemical group 0.000 claims description 8
- 239000013068 control sample Substances 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 claims description 8
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 8
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 8
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 8
- XEMPOAPXKVLKFN-UHFFFAOYSA-N 1-methylpyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2N(C)C=CC2=N1 XEMPOAPXKVLKFN-UHFFFAOYSA-N 0.000 claims description 7
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims description 7
- 125000002393 azetidinyl group Chemical group 0.000 claims description 7
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 7
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 claims description 7
- 125000004095 oxindolyl group Chemical group N1(C(CC2=CC=CC=C12)=O)* 0.000 claims description 7
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- HFTVJMFWJUFBNO-UHFFFAOYSA-N 5h-pyrrolo[2,3-b]pyrazine Chemical compound C1=CN=C2NC=CC2=N1 HFTVJMFWJUFBNO-UHFFFAOYSA-N 0.000 claims description 6
- 208000030814 Eating disease Diseases 0.000 claims description 6
- 230000036506 anxiety Effects 0.000 claims description 6
- 125000005432 dialkylcarboxamide group Chemical group 0.000 claims description 6
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 claims description 6
- 235000014632 disordered eating Nutrition 0.000 claims description 6
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 6
- 125000005942 tetrahydropyridyl group Chemical group 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- VKGAXMRRNWGUFM-HNNXBMFYSA-N [(2s)-2-[5-[2-methoxy-4-(trifluoromethoxy)phenyl]-3,6-dimethylpyrrolo[3,2-b]pyridin-1-yl]butyl] methanesulfonate Chemical compound CC=1C=C2N([C@H](COS(C)(=O)=O)CC)C=C(C)C2=NC=1C1=CC=C(OC(F)(F)F)C=C1OC VKGAXMRRNWGUFM-HNNXBMFYSA-N 0.000 claims description 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- AWGFEIBQECMDIC-ZDUSSCGKSA-N 1-[1-[(2s)-1-methoxypropan-2-yl]-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-6-methylpyrrolo[3,2-b]pyridin-7-yl]pyrrolidine-2,5-dione Chemical compound C=12N([C@@H](C)COC)C=CC2=NC(C=2C(=CC(OC(F)(F)F)=CC=2)OC)=C(C)C=1N1C(=O)CCC1=O AWGFEIBQECMDIC-ZDUSSCGKSA-N 0.000 claims description 3
- BJSJUIAUEBQBJR-ZDUSSCGKSA-N 3-chloro-5-[(2s)-1-methoxypropan-2-yl]-2-(2-methoxy-6-propan-2-ylpyridin-3-yl)-7-methylpyrrolo[2,3-b]pyrazine Chemical compound ClC=1N=C2N([C@@H](C)COC)C=C(C)C2=NC=1C1=CC=C(C(C)C)N=C1OC BJSJUIAUEBQBJR-ZDUSSCGKSA-N 0.000 claims description 3
- SXPZIGSECPJBMG-LBPRGKRZSA-N 3-fluoro-1-[(2s)-1-methoxypropan-2-yl]-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-6-methylpyrrolo[3,2-b]pyridine Chemical compound CC=1C=C2N([C@@H](C)COC)C=C(F)C2=NC=1C1=CC=C(OC(F)(F)F)C=C1OC SXPZIGSECPJBMG-LBPRGKRZSA-N 0.000 claims description 3
- JJBBAPZLAZRJMX-HNNXBMFYSA-N 5-(2-ethyl-6-methoxypyridin-3-yl)-1-[(2s)-1-methoxypropan-2-yl]-3,6-dimethylpyrrolo[3,2-b]pyridine Chemical compound CCC1=NC(OC)=CC=C1C(C(=C1)C)=NC2=C1N([C@@H](C)COC)C=C2C JJBBAPZLAZRJMX-HNNXBMFYSA-N 0.000 claims description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 2
- GMLGLUVWTUJACE-YADHBBJMSA-N 1-[(3r,4s)-4-(2-fluoroethoxy)-1-methylpyrrolidin-3-yl]-5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-3,6-dimethylpyrrolo[3,2-b]pyridine Chemical compound COC1=NC(C(C)C)=CC=C1C(C(=C1)C)=NC2=C1N([C@H]1[C@H](CN(C)C1)OCCF)C=C2C GMLGLUVWTUJACE-YADHBBJMSA-N 0.000 claims description 2
- YIJSZEYGHDZUEE-UHFFFAOYSA-N 2-(2-methoxy-6-propan-2-ylpyridin-3-yl)-3,7-dimethyl-5-propan-2-ylpyrrolo[2,3-b]pyrazine Chemical compound COC1=NC(C(C)C)=CC=C1C(C(=N1)C)=NC2=C1N(C(C)C)C=C2C YIJSZEYGHDZUEE-UHFFFAOYSA-N 0.000 claims description 2
- BIKBEZBEIWFJNS-LBPRGKRZSA-N 3-chloro-1-[(2s)-1-methoxypropan-2-yl]-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-6-methylpyrrolo[3,2-b]pyridine Chemical compound CC=1C=C2N([C@@H](C)COC)C=C(Cl)C2=NC=1C1=CC=C(OC(F)(F)F)C=C1OC BIKBEZBEIWFJNS-LBPRGKRZSA-N 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- JPRSGGQOZPPJDX-UHFFFAOYSA-N 5-(3-chloro-7-methyl-5-pentan-3-ylpyrrolo[2,3-b]pyrazin-2-yl)-4-ethyl-n,n-dimethylpyridin-2-amine Chemical compound ClC=1N=C2N(C(CC)CC)C=C(C)C2=NC=1C1=CN=C(N(C)C)C=C1CC JPRSGGQOZPPJDX-UHFFFAOYSA-N 0.000 claims description 2
- AIGNYRPZHNPUEC-HNNXBMFYSA-N 5-[2-methoxy-4-(trifluoromethoxy)phenyl]-3,6-dimethyl-1-[(2s)-1-methylsulfonylbutan-2-yl]pyrrolo[3,2-b]pyridine Chemical compound CC=1C=C2N([C@H](CS(C)(=O)=O)CC)C=C(C)C2=NC=1C1=CC=C(OC(F)(F)F)C=C1OC AIGNYRPZHNPUEC-HNNXBMFYSA-N 0.000 claims description 2
- RGTFTAHVHBEEIB-UHFFFAOYSA-N 6-(3-chloro-7-methyl-5-pentan-3-ylpyrrolo[2,3-b]pyrazin-2-yl)-5-methoxy-3-propan-2-ylfuro[3,2-b]pyridine Chemical compound ClC=1N=C2N(C(CC)CC)C=C(C)C2=NC=1C(C(=N1)OC)=CC2=C1C(C(C)C)=CO2 RGTFTAHVHBEEIB-UHFFFAOYSA-N 0.000 claims description 2
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- LSDCYFAPMIICFY-UHFFFAOYSA-N cyclopentylcarbamic acid Chemical compound OC(=O)NC1CCCC1 LSDCYFAPMIICFY-UHFFFAOYSA-N 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 238000002825 functional assay Methods 0.000 claims description 2
- 210000002569 neuron Anatomy 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 11
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 9
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 claims 6
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 6
- SMAIQHMIFOIRFB-UHFFFAOYSA-N 1,2-dimethylpyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2N(C)C(C)=CC2=N1 SMAIQHMIFOIRFB-UHFFFAOYSA-N 0.000 claims 4
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 claims 4
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 3
- 125000005947 C1-C6 alkylsulfonyloxy group Chemical group 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 2
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 claims 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 2
- 125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 2
- XENRQXOMBBDKCZ-MRXNPFEDSA-N (2r)-1-[5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-3,6-dimethylpyrrolo[3,2-b]pyridin-1-yl]butan-2-ol Chemical compound CC=1C=C2N(C[C@H](O)CC)C=C(C)C2=NC=1C1=CC=C(C(C)C)N=C1OC XENRQXOMBBDKCZ-MRXNPFEDSA-N 0.000 claims 1
- LTHHZUSIRRDOAB-MRXNPFEDSA-N (2r)-2-[2-(2-chloro-4-methoxyphenyl)-3,7-dimethylpyrrolo[2,3-b]pyrazin-5-yl]-n-ethyl-n-methylbutan-1-amine Chemical compound CC=1N=C2N([C@@H](CN(C)CC)CC)C=C(C)C2=NC=1C1=CC=C(OC)C=C1Cl LTHHZUSIRRDOAB-MRXNPFEDSA-N 0.000 claims 1
- QVZKLCPALQEGFL-CQSZACIVSA-N (2r)-2-[3-chloro-5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-6-methylpyrrolo[3,2-b]pyridin-1-yl]butan-1-ol Chemical compound CC=1C=C2N([C@@H](CO)CC)C=C(Cl)C2=NC=1C1=CC=C(C(C)C)N=C1OC QVZKLCPALQEGFL-CQSZACIVSA-N 0.000 claims 1
- RRDIJFSPKQHODR-QGZVFWFLSA-N (2r)-2-[5-(2-ethoxy-6-ethyl-5-methylsulfonylpyridin-3-yl)-6-ethyl-3-methylpyrrolo[3,2-b]pyridin-1-yl]butan-1-ol Chemical compound CCOC1=NC(CC)=C(S(C)(=O)=O)C=C1C(C(=C1)CC)=NC2=C1N([C@H](CC)CO)C=C2C RRDIJFSPKQHODR-QGZVFWFLSA-N 0.000 claims 1
- LVMCPHWRRJGGNR-OAHLLOKOSA-N (2r)-2-[5-(2-ethoxy-6-ethyl-5-methylsulfonylpyridin-3-yl)-6-ethyl-3-methylpyrrolo[3,2-b]pyridin-1-yl]propan-1-ol Chemical compound CCOC1=NC(CC)=C(S(C)(=O)=O)C=C1C(C(=C1)CC)=NC2=C1N([C@H](C)CO)C=C2C LVMCPHWRRJGGNR-OAHLLOKOSA-N 0.000 claims 1
- WKQQVKVMYRTUGO-OAHLLOKOSA-N (2r)-2-[5-(2-ethyl-6-methoxypyridin-3-yl)-3,6-dimethylpyrrolo[3,2-b]pyridin-1-yl]butan-1-ol Chemical compound CC=1C=C2N([C@@H](CO)CC)C=C(C)C2=NC=1C1=CC=C(OC)N=C1CC WKQQVKVMYRTUGO-OAHLLOKOSA-N 0.000 claims 1
- RGTHSXIYRDMZFA-OAHLLOKOSA-N (2r)-2-[5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-3,6-dimethylpyrrolo[3,2-b]pyridin-1-yl]propan-1-ol Chemical compound COC1=NC(C(C)C)=CC=C1C(C(=C1)C)=NC2=C1N([C@H](C)CO)C=C2C RGTHSXIYRDMZFA-OAHLLOKOSA-N 0.000 claims 1
- QKULNRKASLWVBK-OAHLLOKOSA-N (2r)-2-[5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-6-methylpyrrolo[3,2-b]pyridin-1-yl]butan-1-ol Chemical compound CC=1C=C2N([C@@H](CO)CC)C=CC2=NC=1C1=CC=C(C(C)C)N=C1OC QKULNRKASLWVBK-OAHLLOKOSA-N 0.000 claims 1
- BSUHHUKOJZLGBX-OAHLLOKOSA-N (2r)-2-[6-ethyl-5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-3-methylpyrrolo[3,2-b]pyridin-1-yl]propan-1-ol Chemical compound CCC1=CC=2N([C@H](C)CO)C=C(C)C=2N=C1C1=CC=C(C(C)C)N=C1OC BSUHHUKOJZLGBX-OAHLLOKOSA-N 0.000 claims 1
- TWHTWEBOAZACAM-OAHLLOKOSA-N (2r)-3-methoxy-2-[2-(2-methoxy-6-propan-2-ylpyridin-3-yl)-3,7-dimethylpyrrolo[2,3-b]pyrazin-5-yl]propan-1-ol Chemical compound CC=1N=C2N([C@H](CO)COC)C=C(C)C2=NC=1C1=CC=C(C(C)C)N=C1OC TWHTWEBOAZACAM-OAHLLOKOSA-N 0.000 claims 1
- SOQZGQJZMOXAEA-AWEZNQCLSA-N (2s)-2-[6-bromo-5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-3-methylpyrrolo[3,2-b]pyridin-1-yl]butan-1-ol Chemical compound BrC=1C=C2N([C@H](CO)CC)C=C(C)C2=NC=1C1=CC=C(C(C)C)N=C1OC SOQZGQJZMOXAEA-AWEZNQCLSA-N 0.000 claims 1
- DBVNLQXWPKYAFI-INIZCTEOSA-N (2s)-3-methoxy-2-[5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-3,6-dimethylpyrrolo[3,2-b]pyridin-1-yl]propan-1-ol Chemical compound CC=1C=C2N([C@@H](CO)COC)C=C(C)C2=NC=1C1=CC=C(C(C)C)N=C1OC DBVNLQXWPKYAFI-INIZCTEOSA-N 0.000 claims 1
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 1
- FISYNTJEQPADGC-FQEVSTJZSA-N 1-[(2s)-1-(3,3-dimethylpiperidin-1-yl)butan-2-yl]-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-3,6-dimethylpyrrolo[3,2-b]pyridine Chemical compound C([C@H](CC)N1C2=CC(C)=C(N=C2C(C)=C1)C=1C(=CC(OC(F)(F)F)=CC=1)OC)N1CCCC(C)(C)C1 FISYNTJEQPADGC-FQEVSTJZSA-N 0.000 claims 1
- SEDDFSZTUSQLNM-FQEVSTJZSA-N 1-[(2s)-1-(azepan-1-yl)butan-2-yl]-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-3,6-dimethylpyrrolo[3,2-b]pyridine Chemical compound C([C@H](CC)N1C2=CC(C)=C(N=C2C(C)=C1)C=1C(=CC(OC(F)(F)F)=CC=1)OC)N1CCCCCC1 SEDDFSZTUSQLNM-FQEVSTJZSA-N 0.000 claims 1
- NJOPGINYGSEGID-YADHBBJMSA-N 1-[(3r,4s)-4-(2-fluoroethoxy)-1-methylsulfonylpyrrolidin-3-yl]-5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-3,6-dimethylpyrrolo[3,2-b]pyridine Chemical compound COC1=NC(C(C)C)=CC=C1C(C(=C1)C)=NC2=C1N([C@H]1[C@H](CN(C1)S(C)(=O)=O)OCCF)C=C2C NJOPGINYGSEGID-YADHBBJMSA-N 0.000 claims 1
- VQBIPUYAVBTHAK-UHFFFAOYSA-N 1-butyl-5-(2-ethyl-6-propan-2-ylpyridin-3-yl)-3,6-dimethylpyrrolo[3,2-b]pyridine Chemical compound CC=1C=C2N(CCCC)C=C(C)C2=NC=1C1=CC=C(C(C)C)N=C1CC VQBIPUYAVBTHAK-UHFFFAOYSA-N 0.000 claims 1
- NYACDSKCBJAMAS-UHFFFAOYSA-N 1-butyl-5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-3,6-dimethylpyrrolo[3,2-b]pyridine Chemical compound CC=1C=C2N(CCCC)C=C(C)C2=NC=1C1=CC=C(C(C)C)N=C1OC NYACDSKCBJAMAS-UHFFFAOYSA-N 0.000 claims 1
- BASDOWQNVNYFOM-UHFFFAOYSA-N 1-ethyl-5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-3,6-dimethylpyrrolo[3,2-b]pyridine Chemical compound CC=1C=C2N(CC)C=C(C)C2=NC=1C1=CC=C(C(C)C)N=C1OC BASDOWQNVNYFOM-UHFFFAOYSA-N 0.000 claims 1
- XURZLRKJXZOAGB-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine-3-carbonitrile Chemical compound C1=CN=C2C(C#N)=CNC2=C1 XURZLRKJXZOAGB-UHFFFAOYSA-N 0.000 claims 1
- SFTUZPUXNQAOEU-LJQANCHMSA-N 2,6-diethyl-7-[1-[(2r)-1-methoxybutan-2-yl]-3,6-dimethylpyrrolo[3,2-b]pyridin-5-yl]-4-propan-2-ylpyrido[2,3-b]pyrazin-3-one Chemical compound N1=C(CC)C(=O)N(C(C)C)C(N=C2CC)=C1C=C2C1=C(C)C=C2N([C@@H](COC)CC)C=C(C)C2=N1 SFTUZPUXNQAOEU-LJQANCHMSA-N 0.000 claims 1
- HXNACWNITLCMHI-UHFFFAOYSA-N 2-(2-ethoxy-5-methylsulfonyl-6-pent-4-en-2-ylpyridin-3-yl)-3,7-dimethyl-5-pentan-3-ylpyrrolo[2,3-b]pyrazine Chemical compound CCOC1=NC(C(C)CC=C)=C(S(C)(=O)=O)C=C1C(C(=N1)C)=NC2=C1N(C(CC)CC)C=C2C HXNACWNITLCMHI-UHFFFAOYSA-N 0.000 claims 1
- FRXLBMQRBFUDAM-UHFFFAOYSA-N 2-(2-ethyl-6-propan-2-ylpyridin-3-yl)-3,7-dimethyl-5-propylpyrrolo[2,3-b]pyrazine Chemical compound CC=1N=C2N(CCC)C=C(C)C2=NC=1C1=CC=C(C(C)C)N=C1CC FRXLBMQRBFUDAM-UHFFFAOYSA-N 0.000 claims 1
- KKGMYPLWROEPBW-KRWDZBQOSA-N 2-(2-ethyl-6-propan-2-ylpyridin-3-yl)-5-[(2s)-1-methoxybutan-2-yl]-3,7-dimethylpyrrolo[2,3-b]pyrazine Chemical compound CC=1N=C2N([C@H](COC)CC)C=C(C)C2=NC=1C1=CC=C(C(C)C)N=C1CC KKGMYPLWROEPBW-KRWDZBQOSA-N 0.000 claims 1
- RBOSKUKWORZETB-UHFFFAOYSA-N 2-[2-methoxy-4-(trifluoromethoxy)phenyl]-3,7-dimethyl-5-pentan-3-ylpyrrolo[2,3-b]pyrazine Chemical compound CC=1N=C2N(C(CC)CC)C=C(C)C2=NC=1C1=CC=C(OC(F)(F)F)C=C1OC RBOSKUKWORZETB-UHFFFAOYSA-N 0.000 claims 1
- WTXVNZNDJZYBGG-UHFFFAOYSA-N 2-methoxyethylcarbamic acid Chemical compound COCCNC(O)=O WTXVNZNDJZYBGG-UHFFFAOYSA-N 0.000 claims 1
- ZBNYKOJAOHEVQZ-UHFFFAOYSA-N 3,6-dimethyl-5-(6-propan-2-ylpyridin-3-yl)-1-propylpyrrolo[3,2-b]pyridine Chemical compound CC=1C=C2N(CCC)C=C(C)C2=NC=1C1=CC=C(C(C)C)N=C1 ZBNYKOJAOHEVQZ-UHFFFAOYSA-N 0.000 claims 1
- POQPZQSUZIKJCV-UHFFFAOYSA-N 3-(1-butan-2-yl-3,6-dimethylpyrrolo[3,2-b]pyridin-5-yl)-n-methyl-6-propan-2-ylpyridin-2-amine Chemical compound CC=1C=C2N(C(C)CC)C=C(C)C2=NC=1C1=CC=C(C(C)C)N=C1NC POQPZQSUZIKJCV-UHFFFAOYSA-N 0.000 claims 1
- OFAWQQBQGIGJIA-UHFFFAOYSA-N 3-(1-butyl-3,6-dimethylpyrrolo[3,2-b]pyridin-5-yl)-n-methyl-6-propan-2-ylpyridin-2-amine Chemical compound CC=1C=C2N(CCCC)C=C(C)C2=NC=1C1=CC=C(C(C)C)N=C1NC OFAWQQBQGIGJIA-UHFFFAOYSA-N 0.000 claims 1
- WHNQANIRXJKYCR-UHFFFAOYSA-N 3-(1-ethyl-3,6-dimethylpyrrolo[3,2-b]pyridin-5-yl)-n-methyl-6-propan-2-ylpyridin-2-amine Chemical compound CC=1C=C2N(CC)C=C(C)C2=NC=1C1=CC=C(C(C)C)N=C1NC WHNQANIRXJKYCR-UHFFFAOYSA-N 0.000 claims 1
- XUSBBTHVAAIJMF-UHFFFAOYSA-N 3-(3,6-dimethyl-1-propan-2-ylpyrrolo[3,2-b]pyridin-5-yl)-n,n-dimethyl-6-propan-2-ylpyridin-2-amine Chemical compound CN(C)C1=NC(C(C)C)=CC=C1C(C(=C1)C)=NC2=C1N(C(C)C)C=C2C XUSBBTHVAAIJMF-UHFFFAOYSA-N 0.000 claims 1
- KDSGDSOOIUSTDJ-UHFFFAOYSA-N 3-(3,6-dimethyl-1-propan-2-ylpyrrolo[3,2-b]pyridin-5-yl)-n-methyl-6-propan-2-ylpyridin-2-amine Chemical compound CNC1=NC(C(C)C)=CC=C1C(C(=C1)C)=NC2=C1N(C(C)C)C=C2C KDSGDSOOIUSTDJ-UHFFFAOYSA-N 0.000 claims 1
- OOFICFIVHPGPMH-HXUWFJFHSA-N 3-[3,6-dimethyl-1-[(2r)-1-morpholin-4-ylbutan-2-yl]pyrrolo[3,2-b]pyridin-5-yl]-n-methyl-6-propan-2-ylpyridin-2-amine Chemical compound C([C@@H](CC)N1C2=CC(C)=C(N=C2C(C)=C1)C=1C(=NC(=CC=1)C(C)C)NC)N1CCOCC1 OOFICFIVHPGPMH-HXUWFJFHSA-N 0.000 claims 1
- OOFICFIVHPGPMH-FQEVSTJZSA-N 3-[3,6-dimethyl-1-[(2s)-1-morpholin-4-ylbutan-2-yl]pyrrolo[3,2-b]pyridin-5-yl]-n-methyl-6-propan-2-ylpyridin-2-amine Chemical compound C([C@H](CC)N1C2=CC(C)=C(N=C2C(C)=C1)C=1C(=NC(=CC=1)C(C)C)NC)N1CCOCC1 OOFICFIVHPGPMH-FQEVSTJZSA-N 0.000 claims 1
- MYZRMQNOCHQFMC-ZDUSSCGKSA-N 3-[3-chloro-5-[(2s)-1-methoxypropan-2-yl]-7-methylpyrrolo[2,3-b]pyrazin-2-yl]-n-methyl-6-propan-2-ylpyridin-2-amine Chemical compound CNC1=NC(C(C)C)=CC=C1C(C(=N1)Cl)=NC2=C1N([C@@H](C)COC)C=C2C MYZRMQNOCHQFMC-ZDUSSCGKSA-N 0.000 claims 1
- NIXUIZSVOAFJKY-AWEZNQCLSA-N 3-[6-chloro-1-[(2s)-1-methoxypropan-2-yl]-3-methylpyrrolo[3,2-b]pyridin-5-yl]-n-methyl-6-propan-2-ylpyridin-2-amine Chemical compound CNC1=NC(C(C)C)=CC=C1C(C(=C1)Cl)=NC2=C1N([C@@H](C)COC)C=C2C NIXUIZSVOAFJKY-AWEZNQCLSA-N 0.000 claims 1
- GIGYPNKNFKBGCX-MRXNPFEDSA-N 3-[6-ethyl-1-[(2r)-1-methoxypropan-2-yl]-3-methylpyrrolo[3,2-b]pyridin-5-yl]-n-methyl-6-propan-2-ylpyridin-2-amine Chemical compound CCC1=CC=2N([C@H](C)COC)C=C(C)C=2N=C1C1=CC=C(C(C)C)N=C1NC GIGYPNKNFKBGCX-MRXNPFEDSA-N 0.000 claims 1
- MIXOXSWKLMRXRF-UHFFFAOYSA-N 3-bromo-5-(3,7-dimethyl-5-pentan-3-ylpyrrolo[2,3-b]pyrazin-2-yl)-n,4-diethyl-n-methylpyridin-2-amine Chemical compound CC=1N=C2N(C(CC)CC)C=C(C)C2=NC=1C1=CN=C(N(C)CC)C(Br)=C1CC MIXOXSWKLMRXRF-UHFFFAOYSA-N 0.000 claims 1
- VOCOGJSWPFMTPN-AWEZNQCLSA-N 3-chloro-1-[(2s)-1-methoxypropan-2-yl]-5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-6-methylpyrrolo[3,2-b]pyridine Chemical compound CC=1C=C2N([C@@H](C)COC)C=C(Cl)C2=NC=1C1=CC=C(C(C)C)N=C1OC VOCOGJSWPFMTPN-AWEZNQCLSA-N 0.000 claims 1
- DRAROCBRAGNJRJ-AWEZNQCLSA-N 3-chloro-1-[(2s)-1-methoxypropan-2-yl]-6-methyl-5-(6-propan-2-ylpyridin-3-yl)pyrrolo[3,2-b]pyridine Chemical compound CC=1C=C2N([C@@H](C)COC)C=C(Cl)C2=NC=1C1=CC=C(C(C)C)N=C1 DRAROCBRAGNJRJ-AWEZNQCLSA-N 0.000 claims 1
- KHGNQABBBCRZKJ-HNNXBMFYSA-N 3-ethyl-5-[(2s)-1-methoxypropan-2-yl]-2-(2-methoxy-6-propan-2-ylpyridin-3-yl)-7-methylpyrrolo[2,3-b]pyrazine Chemical compound CCC1=NC=2N([C@@H](C)COC)C=C(C)C=2N=C1C1=CC=C(C(C)C)N=C1OC KHGNQABBBCRZKJ-HNNXBMFYSA-N 0.000 claims 1
- JDFDHBSESGTDAL-UHFFFAOYSA-N 3-methoxypropan-1-ol Chemical compound COCCCO JDFDHBSESGTDAL-UHFFFAOYSA-N 0.000 claims 1
- MVZDNXVMVUKYFE-FQEVSTJZSA-N 4-[(2s)-2-[5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-3,6-dimethylpyrrolo[3,2-b]pyridin-1-yl]butyl]morpholine Chemical compound C([C@H](CC)N1C2=CC(C)=C(N=C2C(C)=C1)C=1C(=NC(=CC=1)C(C)C)OC)N1CCOCC1 MVZDNXVMVUKYFE-FQEVSTJZSA-N 0.000 claims 1
- SXRBBMWSMIISHJ-UHFFFAOYSA-N 4-methoxybutanenitrile Chemical compound COCCCC#N SXRBBMWSMIISHJ-UHFFFAOYSA-N 0.000 claims 1
- MGPQAZVGRKYZNV-KRWDZBQOSA-N 5-(2-ethyl-6-propan-2-yloxypyridin-3-yl)-1-[(2s)-1-methoxypropan-2-yl]-3,6-dimethylpyrrolo[3,2-b]pyridine Chemical compound CCC1=NC(OC(C)C)=CC=C1C(C(=C1)C)=NC2=C1N([C@@H](C)COC)C=C2C MGPQAZVGRKYZNV-KRWDZBQOSA-N 0.000 claims 1
- AKRWGVOKHNUHMM-GOSISDBHSA-N 5-(2-ethyl-6-propan-2-ylpyridin-3-yl)-1-[(2r)-1-methoxybutan-2-yl]-3,6-dimethylpyrrolo[3,2-b]pyridine Chemical compound CC=1C=C2N([C@@H](COC)CC)C=C(C)C2=NC=1C1=CC=C(C(C)C)N=C1CC AKRWGVOKHNUHMM-GOSISDBHSA-N 0.000 claims 1
- DJMBLQFKNGLOHF-KRWDZBQOSA-N 5-(2-ethyl-6-propan-2-ylpyridin-3-yl)-1-[(2s)-1-methoxypropan-2-yl]-3,6-dimethylpyrrolo[3,2-b]pyridine Chemical compound CCC1=NC(C(C)C)=CC=C1C(C(=C1)C)=NC2=C1N([C@@H](C)COC)C=C2C DJMBLQFKNGLOHF-KRWDZBQOSA-N 0.000 claims 1
- QATFVCJVPUJALI-UHFFFAOYSA-N 5-(2-ethyl-6-propan-2-ylpyridin-3-yl)-3,6-dimethyl-1-(2-methylpropyl)pyrrolo[3,2-b]pyridine Chemical compound CCC1=NC(C(C)C)=CC=C1C(C(=C1)C)=NC2=C1N(CC(C)C)C=C2C QATFVCJVPUJALI-UHFFFAOYSA-N 0.000 claims 1
- BRRYOWQCLPLFME-UHFFFAOYSA-N 5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-1,3,6-trimethylpyrrolo[3,2-b]pyridine Chemical compound COC1=NC(C(C)C)=CC=C1C(C(=C1)C)=NC2=C1N(C)C=C2C BRRYOWQCLPLFME-UHFFFAOYSA-N 0.000 claims 1
- OOFULEJUQPYEHB-UHFFFAOYSA-N 5-(3,7-dimethyl-5-pentan-3-ylpyrrolo[2,3-b]pyrazin-2-yl)-n,4-diethyl-n-methylpyridin-2-amine Chemical compound CC=1N=C2N(C(CC)CC)C=C(C)C2=NC=1C1=CN=C(N(C)CC)C=C1CC OOFULEJUQPYEHB-UHFFFAOYSA-N 0.000 claims 1
- JYQVVBFTFIMJRQ-UHFFFAOYSA-N 5-(3-chloro-7-methyl-5-pentan-3-ylpyrrolo[2,3-b]pyrazin-2-yl)-n,4-diethyl-n-methylpyridin-2-amine Chemical compound ClC=1N=C2N(C(CC)CC)C=C(C)C2=NC=1C1=CN=C(N(C)CC)C=C1CC JYQVVBFTFIMJRQ-UHFFFAOYSA-N 0.000 claims 1
- HVELZZIJZOWEEQ-LJQANCHMSA-N 5-[2-(azetidin-1-yl)-6-propan-2-ylpyridin-3-yl]-1-[(2r)-1-methoxybutan-2-yl]-3,6-dimethylpyrrolo[3,2-b]pyridine Chemical compound CC=1C=C2N([C@@H](COC)CC)C=C(C)C2=NC=1C1=CC=C(C(C)C)N=C1N1CCC1 HVELZZIJZOWEEQ-LJQANCHMSA-N 0.000 claims 1
- ILPUKNBASIZXRD-HXUWFJFHSA-N 5-[2-(azetidin-1-yl)-6-propan-2-ylpyridin-3-yl]-6-ethyl-1-[(2r)-1-methoxybutan-2-yl]-3-methylpyrrolo[3,2-b]pyridine Chemical compound CCC=1C=C2N([C@@H](COC)CC)C=C(C)C2=NC=1C1=CC=C(C(C)C)N=C1N1CCC1 ILPUKNBASIZXRD-HXUWFJFHSA-N 0.000 claims 1
- YRDSHJLAAKUPPS-IBGZPJMESA-N 5-[2-methoxy-4-(trifluoromethoxy)phenyl]-3,6-dimethyl-1-[(2s)-1-piperidin-1-ylbutan-2-yl]pyrrolo[3,2-b]pyridine Chemical compound C([C@H](CC)N1C2=CC(C)=C(N=C2C(C)=C1)C=1C(=CC(OC(F)(F)F)=CC=1)OC)N1CCCCC1 YRDSHJLAAKUPPS-IBGZPJMESA-N 0.000 claims 1
- VUVWOBORYVROMA-UHFFFAOYSA-N 5-bromo-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-1-methyl-3-pentan-3-ylpyrrolo[2,3-b]pyridine Chemical compound BrC=1C=C2C(C(CC)CC)=CN(C)C2=NC=1C1=CC=C(OC(F)(F)F)C=C1OC VUVWOBORYVROMA-UHFFFAOYSA-N 0.000 claims 1
- XOIOAGDHULRXGP-UHFFFAOYSA-N 5-chloro-3-(3,6-dimethyl-1-propan-2-ylpyrrolo[3,2-b]pyridin-5-yl)-n-ethyl-6-propan-2-ylpyridin-2-amine Chemical compound CCNC1=NC(C(C)C)=C(Cl)C=C1C(C(=C1)C)=NC2=C1N(C(C)C)C=C2C XOIOAGDHULRXGP-UHFFFAOYSA-N 0.000 claims 1
- GGHNFQROIOWAMJ-UHFFFAOYSA-N 6-[2-methoxy-4-(trifluoromethoxy)phenyl]-1,5-dimethyl-3-pentan-3-ylpyrrolo[2,3-b]pyridine Chemical compound CC=1C=C2C(C(CC)CC)=CN(C)C2=NC=1C1=CC=C(OC(F)(F)F)C=C1OC GGHNFQROIOWAMJ-UHFFFAOYSA-N 0.000 claims 1
- LOYSZMCHLFVUPX-HNNXBMFYSA-N 6-chloro-5-(2-ethyl-6-propan-2-ylpyridin-3-yl)-1-[(2s)-1-methoxypropan-2-yl]-3-methylpyrrolo[3,2-b]pyridine Chemical compound CCC1=NC(C(C)C)=CC=C1C(C(=C1)Cl)=NC2=C1N([C@@H](C)COC)C=C2C LOYSZMCHLFVUPX-HNNXBMFYSA-N 0.000 claims 1
- GEXGMAHPJDMLJI-MRXNPFEDSA-N 6-ethyl-1-[(2r)-1-fluoropropan-2-yl]-5-(2-methoxy-4-propan-2-ylphenyl)-3-methylpyrrolo[3,2-b]pyridine Chemical compound CCC1=CC=2N([C@H](C)CF)C=C(C)C=2N=C1C1=CC=C(C(C)C)C=C1OC GEXGMAHPJDMLJI-MRXNPFEDSA-N 0.000 claims 1
- AGKNKHOVXYLXGD-QGZVFWFLSA-N 6-ethyl-1-[(2r)-1-methoxypropan-2-yl]-5-(2-methoxy-4-propan-2-ylphenyl)-3-methylpyrrolo[3,2-b]pyridine Chemical compound CCC1=CC=2N([C@H](C)COC)C=C(C)C=2N=C1C1=CC=C(C(C)C)C=C1OC AGKNKHOVXYLXGD-QGZVFWFLSA-N 0.000 claims 1
- RYFDUQLUWOMJBO-INIZCTEOSA-N 6-ethyl-1-[(2s)-1-methoxypropan-2-yl]-5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-3-methylpyrrolo[3,2-b]pyridine Chemical compound CCC1=CC=2N([C@@H](C)COC)C=C(C)C=2N=C1C1=CC=C(C(C)C)N=C1OC RYFDUQLUWOMJBO-INIZCTEOSA-N 0.000 claims 1
- DOONOYDSPGMBNN-INIZCTEOSA-N 6-ethyl-5-[1-[(2s)-1-methoxypropan-2-yl]-3,6-dimethylpyrrolo[3,2-b]pyridin-5-yl]-n,n-dimethylpyridin-2-amine Chemical compound CCC1=NC(N(C)C)=CC=C1C(C(=C1)C)=NC2=C1N([C@@H](C)COC)C=C2C DOONOYDSPGMBNN-INIZCTEOSA-N 0.000 claims 1
- CMVFHSXRPSQLGG-GOSISDBHSA-N 6-ethyl-7-[1-[(2r)-1-hydroxybutan-2-yl]-3,6-dimethylpyrrolo[3,2-b]pyridin-5-yl]-2-methyl-4-propan-2-ylpyrido[2,3-b]pyrazin-3-one Chemical compound N1=C(C)C(=O)N(C(C)C)C(N=C2CC)=C1C=C2C1=C(C)C=C2N([C@@H](CO)CC)C=C(C)C2=N1 CMVFHSXRPSQLGG-GOSISDBHSA-N 0.000 claims 1
- SOLHJJQRCDOQNG-HXUWFJFHSA-N 6-ethyl-7-[1-[(2r)-1-methoxybutan-2-yl]-3,6-dimethylpyrrolo[3,2-b]pyridin-5-yl]-2,4-di(propan-2-yl)pyrido[2,3-b]pyrazin-3-one Chemical compound N1=C(C(C)C)C(=O)N(C(C)C)C(N=C2CC)=C1C=C2C1=C(C)C=C2N([C@@H](COC)CC)C=C(C)C2=N1 SOLHJJQRCDOQNG-HXUWFJFHSA-N 0.000 claims 1
- APRJFNLVTJWEPP-UHFFFAOYSA-N Diethylcarbamic acid Chemical compound CCN(CC)C(O)=O APRJFNLVTJWEPP-UHFFFAOYSA-N 0.000 claims 1
- XVVCAKGMAVBCNQ-IBGZPJMESA-N [(2s)-2-[5-[2-methoxy-4-(trifluoromethoxy)phenyl]-3,6-dimethylpyrrolo[3,2-b]pyridin-1-yl]butyl] n-ethyl-n-(2-methoxyethyl)carbamate Chemical compound CC=1C=C2N([C@H](COC(=O)N(CC)CCOC)CC)C=C(C)C2=NC=1C1=CC=C(OC(F)(F)F)C=C1OC XVVCAKGMAVBCNQ-IBGZPJMESA-N 0.000 claims 1
- GAGCCGCZBDFUQH-KRWDZBQOSA-N [(2s)-2-[5-[2-methoxy-4-(trifluoromethoxy)phenyl]-3,6-dimethylpyrrolo[3,2-b]pyridin-1-yl]butyl] n-ethyl-n-methylcarbamate Chemical compound CC=1C=C2N([C@H](COC(=O)N(C)CC)CC)C=C(C)C2=NC=1C1=CC=C(OC(F)(F)F)C=C1OC GAGCCGCZBDFUQH-KRWDZBQOSA-N 0.000 claims 1
- MEOZFUYXLCDYGA-UHFFFAOYSA-N azepane-1-carboxylic acid Chemical compound OC(=O)N1CCCCCC1 MEOZFUYXLCDYGA-UHFFFAOYSA-N 0.000 claims 1
- VKEOLSRHORITAD-UHFFFAOYSA-N ethyl 2-[5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-3,6-dimethylpyrrolo[3,2-b]pyridin-1-yl]acetate Chemical compound CC=1C=C2N(CC(=O)OCC)C=C(C)C2=NC=1C1=CC=C(C(C)C)N=C1OC VKEOLSRHORITAD-UHFFFAOYSA-N 0.000 claims 1
- XIKDEXWRZLRDKE-CTNGQTDRSA-N methyl (3s,4r)-3-(2-fluoroethoxy)-4-[5-[2-methoxy-4-(trifluoromethoxy)phenyl]-3,6-dimethylpyrrolo[3,2-b]pyridin-1-yl]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC)C[C@H](OCCF)[C@@H]1N1C2=CC(C)=C(C=3C(=CC(OC(F)(F)F)=CC=3)OC)N=C2C(C)=C1 XIKDEXWRZLRDKE-CTNGQTDRSA-N 0.000 claims 1
- GVSXJLYHRYMJNY-KRWDZBQOSA-N n-ethyl-3-[1-[(2r)-1-fluoro-3-methoxypropan-2-yl]-3,6-dimethylpyrrolo[3,2-b]pyridin-5-yl]-6-propan-2-ylpyridin-2-amine Chemical compound CCNC1=NC(C(C)C)=CC=C1C(C(=C1)C)=NC2=C1N([C@@H](CF)COC)C=C2C GVSXJLYHRYMJNY-KRWDZBQOSA-N 0.000 claims 1
- GCSMZSULZUXJCN-INIZCTEOSA-N n-ethyl-3-[6-methoxy-1-[(2s)-1-methoxypropan-2-yl]-3-methylpyrrolo[3,2-b]pyridin-5-yl]-6-propan-2-ylpyridin-2-amine Chemical compound CCNC1=NC(C(C)C)=CC=C1C(C(=C1)OC)=NC2=C1N([C@@H](C)COC)C=C2C GCSMZSULZUXJCN-INIZCTEOSA-N 0.000 claims 1
- JAELLLITIZHOGQ-UHFFFAOYSA-N tert-butyl propanoate Chemical compound CCC(=O)OC(C)(C)C JAELLLITIZHOGQ-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 297
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 212
- 235000019439 ethyl acetate Nutrition 0.000 description 132
- 229910001868 water Inorganic materials 0.000 description 132
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 129
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 122
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 96
- 239000000243 solution Substances 0.000 description 90
- 238000000746 purification Methods 0.000 description 87
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 83
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 78
- 239000000741 silica gel Substances 0.000 description 78
- 229910002027 silica gel Inorganic materials 0.000 description 78
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 64
- 239000011541 reaction mixture Substances 0.000 description 63
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 60
- 239000012267 brine Substances 0.000 description 58
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 58
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 52
- 239000011734 sodium Substances 0.000 description 46
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 44
- 238000003786 synthesis reaction Methods 0.000 description 44
- 230000015572 biosynthetic process Effects 0.000 description 43
- 238000006243 chemical reaction Methods 0.000 description 42
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 41
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 40
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 40
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- 239000000047 product Substances 0.000 description 36
- 239000012044 organic layer Substances 0.000 description 34
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 33
- 238000003756 stirring Methods 0.000 description 32
- 238000003818 flash chromatography Methods 0.000 description 27
- 230000002829 reductive effect Effects 0.000 description 27
- 239000002904 solvent Substances 0.000 description 27
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 26
- 235000019341 magnesium sulphate Nutrition 0.000 description 26
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 22
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 22
- 229910052938 sodium sulfate Inorganic materials 0.000 description 22
- 235000011152 sodium sulphate Nutrition 0.000 description 22
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 21
- 229910000104 sodium hydride Inorganic materials 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 20
- 208000035475 disorder Diseases 0.000 description 20
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 18
- 239000011159 matrix material Substances 0.000 description 18
- 239000012043 crude product Substances 0.000 description 17
- 238000007872 degassing Methods 0.000 description 17
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 17
- 238000001704 evaporation Methods 0.000 description 16
- 230000008020 evaporation Effects 0.000 description 16
- 239000000284 extract Substances 0.000 description 16
- 229920000728 polyester Polymers 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000003921 oil Substances 0.000 description 15
- 235000019198 oils Nutrition 0.000 description 15
- 238000001035 drying Methods 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 13
- 239000007858 starting material Substances 0.000 description 13
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 125000000304 alkynyl group Chemical group 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 11
- 238000012746 preparative thin layer chromatography Methods 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- 229910000029 sodium carbonate Inorganic materials 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- 125000003342 alkenyl group Chemical group 0.000 description 9
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 9
- 239000013058 crude material Substances 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 231100000252 nontoxic Toxicity 0.000 description 9
- 230000003000 nontoxic effect Effects 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 125000001246 bromo group Chemical group Br* 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 7
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 7
- PPYRIPJLBOJUNH-UHFFFAOYSA-N 2-methoxy-6-propan-2-ylpyridine Chemical compound COC1=CC=CC(C(C)C)=N1 PPYRIPJLBOJUNH-UHFFFAOYSA-N 0.000 description 6
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 6
- 241001553178 Arachis glabrata Species 0.000 description 6
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 208000019022 Mood disease Diseases 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical class CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 5
- 230000000949 anxiolytic effect Effects 0.000 description 5
- 230000003542 behavioural effect Effects 0.000 description 5
- 229940049706 benzodiazepine Drugs 0.000 description 5
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 239000002769 corticotropin releasing factor antagonist Substances 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 5
- 239000006199 nebulizer Substances 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- VUIJGYPRRJGNPI-UHFFFAOYSA-N (2-methoxy-6-propan-2-ylpyridin-3-yl)boronic acid Chemical compound COC1=NC(C(C)C)=CC=C1B(O)O VUIJGYPRRJGNPI-UHFFFAOYSA-N 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- MTLCJOOCTPJNNV-ZDUSSCGKSA-N 1-[(2s)-1-methoxypropan-2-yl]-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-6-methylpyrrolo[3,2-b]pyridine Chemical compound CC=1C=C2N([C@@H](C)COC)C=CC2=NC=1C1=CC=C(OC(F)(F)F)C=C1OC MTLCJOOCTPJNNV-ZDUSSCGKSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- AJCQJELUJDPGEY-UHFFFAOYSA-N [2-methoxy-4-(trifluoromethoxy)phenyl]boronic acid Chemical compound COC1=CC(OC(F)(F)F)=CC=C1B(O)O AJCQJELUJDPGEY-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 125000001589 carboacyl group Chemical group 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 125000001624 naphthyl group Chemical group 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229940086542 triethylamine Drugs 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- ZRNUFTUQKYCICK-AWEZNQCLSA-N (2s)-2-[5-[2-methoxy-4-(trifluoromethoxy)phenyl]-3,6-dimethylpyrrolo[3,2-b]pyridin-1-yl]butan-1-ol Chemical compound CC=1C=C2N([C@H](CO)CC)C=C(C)C2=NC=1C1=CC=C(OC(F)(F)F)C=C1OC ZRNUFTUQKYCICK-AWEZNQCLSA-N 0.000 description 3
- APCNDIHSONQMLV-RTWAWAEBSA-N 1-[(3r,4s)-4-(2-fluoroethoxy)pyrrolidin-3-yl]-5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-3,6-dimethylpyrrolo[3,2-b]pyridine Chemical compound COC1=NC(C(C)C)=CC=C1C(C(=C1)C)=NC2=C1N([C@H]1[C@H](CNC1)OCCF)C=C2C APCNDIHSONQMLV-RTWAWAEBSA-N 0.000 description 3
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 3
- LIMXEVCFAUTBCK-UHFFFAOYSA-N 2,5-dibromo-3-methylpyridine Chemical compound CC1=CC(Br)=CN=C1Br LIMXEVCFAUTBCK-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- PUKHGPXUBABAME-UHFFFAOYSA-N 5-bromo-2-[2-methoxy-4-(trifluoromethoxy)phenyl]-3-methylpyridine Chemical compound COC1=CC(OC(F)(F)F)=CC=C1C1=NC=C(Br)C=C1C PUKHGPXUBABAME-UHFFFAOYSA-N 0.000 description 3
- GTBBOAUCPFNIBQ-UHFFFAOYSA-N 5-bromo-6-ethyl-2-n-propan-2-ylpyridine-2,3-diamine Chemical compound CCC1=NC(NC(C)C)=C(N)C=C1Br GTBBOAUCPFNIBQ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 101100037762 Caenorhabditis elegans rnh-2 gene Proteins 0.000 description 3
- 229940122010 Corticotropin releasing factor antagonist Drugs 0.000 description 3
- 206010013883 Dwarfism Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 101150003085 Pdcl gene Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 239000002249 anxiolytic agent Substances 0.000 description 3
- 229940005530 anxiolytics Drugs 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 238000000211 autoradiogram Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 150000002828 nitro derivatives Chemical class 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- XFTQRUTUGRCSGO-UHFFFAOYSA-N pyrazin-2-amine Chemical compound NC1=CN=CC=N1 XFTQRUTUGRCSGO-UHFFFAOYSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- LALRXNPLTWZJIJ-UHFFFAOYSA-N triethylborane Chemical compound CCB(CC)CC LALRXNPLTWZJIJ-UHFFFAOYSA-N 0.000 description 3
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- NXMXETCTWNXSFG-BYPYZUCNSA-N (2s)-1-methoxypropan-2-amine Chemical compound COC[C@H](C)N NXMXETCTWNXSFG-BYPYZUCNSA-N 0.000 description 2
- FRHPAXDEWMMDAP-UHFFFAOYSA-N (4-methoxypyridin-2-yl) trifluoromethanesulfonate Chemical compound COC1=CC=NC(OS(=O)(=O)C(F)(F)F)=C1 FRHPAXDEWMMDAP-UHFFFAOYSA-N 0.000 description 2
- PSDREHBPEVJWGI-AWEZNQCLSA-N 1-[(2s)-1-chlorobutan-2-yl]-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-3,6-dimethylpyrrolo[3,2-b]pyridine Chemical compound CC=1C=C2N([C@H](CCl)CC)C=C(C)C2=NC=1C1=CC=C(OC(F)(F)F)C=C1OC PSDREHBPEVJWGI-AWEZNQCLSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- YPDUJFLUTSACKH-UHFFFAOYSA-N 2,5-dibromo-6-ethyl-3-nitropyridine Chemical compound CCC1=NC(Br)=C([N+]([O-])=O)C=C1Br YPDUJFLUTSACKH-UHFFFAOYSA-N 0.000 description 2
- UCDGDYVDDIPKMD-UHFFFAOYSA-N 2-(2-ethyl-6-propan-2-ylpyridin-3-yl)-3,7-dimethyl-5-propan-2-ylpyrrolo[2,3-b]pyrazine Chemical compound CCC1=NC(C(C)C)=CC=C1C(C(=N1)C)=NC2=C1N(C(C)C)C=C2C UCDGDYVDDIPKMD-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- NGSQLXNYUUMEIO-UHFFFAOYSA-N 3,5-dibromo-6-ethylpyridin-2-amine Chemical compound CCC1=NC(N)=C(Br)C=C1Br NGSQLXNYUUMEIO-UHFFFAOYSA-N 0.000 description 2
- FJSFPDRDFLAPGN-UHFFFAOYSA-N 3-(3,7-dimethyl-5-propan-2-ylpyrrolo[2,3-b]pyrazin-2-yl)-n-methyl-6-propan-2-ylpyridin-2-amine Chemical compound CNC1=NC(C(C)C)=CC=C1C(C(=N1)C)=NC2=C1N(C(C)C)C=C2C FJSFPDRDFLAPGN-UHFFFAOYSA-N 0.000 description 2
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 2
- UZZILCFUGXUHIG-AWEZNQCLSA-N 3-bromo-1-[(2s)-1-methoxypropan-2-yl]-5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-6-methylpyrrolo[3,2-b]pyridine Chemical compound CC=1C=C2N([C@@H](C)COC)C=C(Br)C2=NC=1C1=CC=C(C(C)C)N=C1OC UZZILCFUGXUHIG-AWEZNQCLSA-N 0.000 description 2
- SUERSWMCYWUEDW-UHFFFAOYSA-N 3-bromo-2-ethoxy-6-ethyl-5-methylsulfonylpyridine Chemical compound CCOC1=NC(CC)=C(S(C)(=O)=O)C=C1Br SUERSWMCYWUEDW-UHFFFAOYSA-N 0.000 description 2
- JOPJZYVHFBMFQU-UHFFFAOYSA-N 3-bromo-6-ethyl-5-methylsulfonylpyridin-2-amine Chemical compound CCC1=NC(N)=C(Br)C=C1S(C)(=O)=O JOPJZYVHFBMFQU-UHFFFAOYSA-N 0.000 description 2
- VTOQFOCYBTVOJZ-UHFFFAOYSA-N 3-bromopentane Chemical compound CCC(Br)CC VTOQFOCYBTVOJZ-UHFFFAOYSA-N 0.000 description 2
- AGVPSBDCZREIHN-UHFFFAOYSA-N 4-methoxy-n,n-dimethylpyridin-2-amine Chemical compound COC1=CC=NC(N(C)C)=C1 AGVPSBDCZREIHN-UHFFFAOYSA-N 0.000 description 2
- AYTPPZQSGUONRB-UHFFFAOYSA-N 5-bromo-2-(2-methoxy-6-propan-2-ylpyridin-3-yl)-3,4-dimethylpyridine Chemical compound COC1=NC(C(C)C)=CC=C1C1=NC=C(Br)C(C)=C1C AYTPPZQSGUONRB-UHFFFAOYSA-N 0.000 description 2
- PTIDDSJVNIIEGL-UHFFFAOYSA-N 5-bromo-3,4-dimethyl-1h-pyridin-2-one Chemical compound CC1=C(C)C(O)=NC=C1Br PTIDDSJVNIIEGL-UHFFFAOYSA-N 0.000 description 2
- FBMFJZQNQGJFQB-UHFFFAOYSA-N 5-bromo-6-ethyl-3-nitro-n-propan-2-ylpyridin-2-amine Chemical compound CCC1=NC(NC(C)C)=C([N+]([O-])=O)C=C1Br FBMFJZQNQGJFQB-UHFFFAOYSA-N 0.000 description 2
- VWPDZMUQRAGOQK-UHFFFAOYSA-N 5-bromo-6-ethyl-3-nitropyridin-2-amine Chemical compound CCC1=NC(N)=C([N+]([O-])=O)C=C1Br VWPDZMUQRAGOQK-UHFFFAOYSA-N 0.000 description 2
- SYFQQSLPNGTEMV-UHFFFAOYSA-N 5-bromo-6-ethylpyridin-2-amine Chemical compound CCC1=NC(N)=CC=C1Br SYFQQSLPNGTEMV-UHFFFAOYSA-N 0.000 description 2
- JRMKAUZPIFQOAY-UHFFFAOYSA-N 6-bromo-5-ethyl-3-propan-2-ylimidazo[4,5-b]pyridine Chemical compound C1=C(Br)C(CC)=NC2=C1N=CN2C(C)C JRMKAUZPIFQOAY-UHFFFAOYSA-N 0.000 description 2
- JXKAUUVMXZIJNZ-UHFFFAOYSA-N 6-ethylpyridin-2-amine Chemical compound CCC1=CC=CC(N)=N1 JXKAUUVMXZIJNZ-UHFFFAOYSA-N 0.000 description 2
- WDUQRIVDVQTVTJ-UHFFFAOYSA-N 7-bromo-6-ethyl-2-methyl-4-propan-2-ylpyrido[2,3-b]pyrazin-3-one Chemical compound CC(C)N1C(=O)C(C)=NC2=C1N=C(CC)C(Br)=C2 WDUQRIVDVQTVTJ-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- 208000017194 Affective disease Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 2
- 108091005470 CRHR2 Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 102100038018 Corticotropin-releasing factor receptor 1 Human genes 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 101100520660 Drosophila melanogaster Poc1 gene Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000878678 Homo sapiens Corticotropin-releasing factor receptor 1 Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 101000663001 Mus musculus TNFAIP3-interacting protein 1 Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 2
- 239000000683 Pro-Opiomelanocortin Substances 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 101100520662 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PBA1 gene Proteins 0.000 description 2
- 101000948733 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Probable phospholipid translocase non-catalytic subunit CRF1 Proteins 0.000 description 2
- 208000013200 Stress disease Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 206010048327 Supranuclear palsy Diseases 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- LQJFFSGDIXXQCZ-IBGZPJMESA-N [(2s)-2-[5-[2-methoxy-4-(trifluoromethoxy)phenyl]-3,6-dimethylpyrrolo[3,2-b]pyridin-1-yl]butyl] piperidine-1-carboxylate Chemical compound C([C@H](CC)N1C2=CC(C)=C(N=C2C(C)=C1)C=1C(=CC(OC(F)(F)F)=CC=1)OC)OC(=O)N1CCCCC1 LQJFFSGDIXXQCZ-IBGZPJMESA-N 0.000 description 2
- YYKBBFZVNQTPHA-UHFFFAOYSA-N [6-(dimethylamino)-4-ethylpyridin-3-yl]boronic acid Chemical compound CCC1=CC(N(C)C)=NC=C1B(O)O YYKBBFZVNQTPHA-UHFFFAOYSA-N 0.000 description 2
- NEKJUWAYMREFEB-UHFFFAOYSA-N [6-(dimethylamino)-4-methoxypyridin-3-yl]boronic acid Chemical compound COC1=CC(N(C)C)=NC=C1B(O)O NEKJUWAYMREFEB-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- HFEHLDPGIKPNKL-UHFFFAOYSA-N allyl iodide Chemical compound ICC=C HFEHLDPGIKPNKL-UHFFFAOYSA-N 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000338 anxiogenic effect Effects 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- JPLUJHOISCAQAB-CVEARBPZSA-N benzyl (3r,4s)-3-amino-4-[tert-butyl(dimethyl)silyl]oxypyrrolidine-1-carboxylate Chemical compound C1[C@@H](N)[C@@H](O[Si](C)(C)C(C)(C)C)CN1C(=O)OCC1=CC=CC=C1 JPLUJHOISCAQAB-CVEARBPZSA-N 0.000 description 2
- KVVOGBABZORBND-IZLXSDGUSA-N benzyl (3s,4r)-3-(2-fluoroethoxy)-4-[5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-3,6-dimethylpyrrolo[3,2-b]pyridin-1-yl]pyrrolidine-1-carboxylate Chemical compound COC1=NC(C(C)C)=CC=C1C(C(=C1)C)=NC2=C1N([C@H]1[C@H](CN(C1)C(=O)OCC=1C=CC=CC=1)OCCF)C=C2C KVVOGBABZORBND-IZLXSDGUSA-N 0.000 description 2
- KGOJMYNJOQRGCL-WDYNHAJCSA-N benzyl (3s,4r)-3-[tert-butyl(dimethyl)silyl]oxy-4-[[6-(2-methoxy-6-propan-2-ylpyridin-3-yl)-5-methylpyridin-3-yl]amino]pyrrolidine-1-carboxylate Chemical compound COC1=NC(C(C)C)=CC=C1C(C(=C1)C)=NC=C1N[C@H]1[C@@H](O[Si](C)(C)C(C)(C)C)CN(C(=O)OCC=2C=CC=CC=2)C1 KGOJMYNJOQRGCL-WDYNHAJCSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 2
- 238000004807 desolvation Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- DWLVWMUCHSLGSU-UHFFFAOYSA-N dimethylcarbamic acid Chemical compound CN(C)C(O)=O DWLVWMUCHSLGSU-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000012039 electrophile Substances 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 238000004401 flow injection analysis Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 2
- AOGQPLXWSUTHQB-UHFFFAOYSA-N hexyl acetic acid ester Natural products CCCCCCOC(C)=O AOGQPLXWSUTHQB-UHFFFAOYSA-N 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- MLSKXPOBNQFGHW-UHFFFAOYSA-N methoxy(dioxido)borane Chemical compound COB([O-])[O-] MLSKXPOBNQFGHW-UHFFFAOYSA-N 0.000 description 2
- MIWLNMRIXOXROW-YADHBBJMSA-N methyl (3s,4r)-3-(2-fluoroethoxy)-4-[5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-3,6-dimethylpyrrolo[3,2-b]pyridin-1-yl]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC)C[C@H](OCCF)[C@@H]1N1C2=CC(C)=C(C=3C(=NC(=CC=3)C(C)C)OC)N=C2C(C)=C1 MIWLNMRIXOXROW-YADHBBJMSA-N 0.000 description 2
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- SYXYWTXQFUUWLP-UHFFFAOYSA-N sodium;butan-1-olate Chemical compound [Na+].CCCC[O-] SYXYWTXQFUUWLP-UHFFFAOYSA-N 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000012289 standard assay Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- SSJXIUAHEKJCMH-PHDIDXHHSA-N (1r,2r)-cyclohexane-1,2-diamine Chemical compound N[C@@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-PHDIDXHHSA-N 0.000 description 1
- KRWNDTAVKGMNDQ-SCSAIBSYSA-N (2r)-2-amino-3-methoxypropan-1-ol Chemical compound COC[C@H](N)CO KRWNDTAVKGMNDQ-SCSAIBSYSA-N 0.000 description 1
- NIPVWKZBILGKCT-PGMHMLKASA-N (2r)-2-amino-3-methoxypropan-1-ol;hydrochloride Chemical compound Cl.COC[C@H](N)CO NIPVWKZBILGKCT-PGMHMLKASA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- PRRIGGBFRPGBRY-UHFFFAOYSA-N (3-diphenylphosphanyl-1-naphthalen-1-ylnaphthalen-2-yl)-diphenylphosphane Chemical group C1=CC=CC=C1P(C=1C(=C(C=2C3=CC=CC=C3C=CC=2)C2=CC=CC=C2C=1)P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 PRRIGGBFRPGBRY-UHFFFAOYSA-N 0.000 description 1
- QDJPBFLSWVIGQY-UHFFFAOYSA-N (6-methoxy-2-propan-2-ylpyridin-3-yl)boronic acid Chemical compound COC1=CC=C(B(O)O)C(C(C)C)=N1 QDJPBFLSWVIGQY-UHFFFAOYSA-N 0.000 description 1
- 125000006529 (C3-C6) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- ITZDIINMLAOWGG-MRXNPFEDSA-N 1-[(2s)-1-fluoro-3-methoxypropan-2-yl]-5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-3,6-dimethylpyrrolo[3,2-b]pyridine Chemical compound CC=1C=C2N([C@H](CF)COC)C=C(C)C2=NC=1C1=CC=C(C(C)C)N=C1OC ITZDIINMLAOWGG-MRXNPFEDSA-N 0.000 description 1
- IMZUXKIHQMUHDC-HNNXBMFYSA-N 1-[(2s)-1-methoxybutan-2-yl]-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-3,6-dimethylpyrrolo[3,2-b]pyridine Chemical compound CC=1C=C2N([C@H](COC)CC)C=C(C)C2=NC=1C1=CC=C(OC(F)(F)F)C=C1OC IMZUXKIHQMUHDC-HNNXBMFYSA-N 0.000 description 1
- QEKMJLXEUSWIMQ-HNNXBMFYSA-N 1-[(2s)-1-methoxypropan-2-yl]-5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-3,6,7-trimethylpyrrolo[3,2-b]pyridine Chemical compound CC=1C(C)=C2N([C@@H](C)COC)C=C(C)C2=NC=1C1=CC=C(C(C)C)N=C1OC QEKMJLXEUSWIMQ-HNNXBMFYSA-N 0.000 description 1
- SPRSJUDLZIKCAR-HNNXBMFYSA-N 1-[(2s)-1-methoxypropan-2-yl]-5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-6-methylpyrrolo[3,2-b]pyridine-3-carbonitrile Chemical compound CC=1C=C2N([C@@H](C)COC)C=C(C#N)C2=NC=1C1=CC=C(C(C)C)N=C1OC SPRSJUDLZIKCAR-HNNXBMFYSA-N 0.000 description 1
- DBGSRZSKGVSXRK-UHFFFAOYSA-N 1-[2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]acetyl]-3,6-dihydro-2H-pyridine-4-carboxylic acid Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CCC(=CC1)C(=O)O DBGSRZSKGVSXRK-UHFFFAOYSA-N 0.000 description 1
- ZVHZPFSWZWSDEN-UHFFFAOYSA-N 1-bromo-1-fluoroethane Chemical compound CC(F)Br ZVHZPFSWZWSDEN-UHFFFAOYSA-N 0.000 description 1
- LOYZVRIHVZEDMW-UHFFFAOYSA-N 1-bromo-3-methylbut-2-ene Chemical compound CC(C)=CCBr LOYZVRIHVZEDMW-UHFFFAOYSA-N 0.000 description 1
- OKSRAPDSZKICKZ-UHFFFAOYSA-N 1-methoxy-3-(trifluoromethoxy)benzene Chemical compound COC1=CC=CC(OC(F)(F)F)=C1 OKSRAPDSZKICKZ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- YFVZIDWCXCIAEC-UHFFFAOYSA-N 1-methylpyrrolo[3,2-b]pyridine-3-carbaldehyde Chemical compound C1=CC=C2N(C)C=C(C=O)C2=N1 YFVZIDWCXCIAEC-UHFFFAOYSA-N 0.000 description 1
- 125000005955 1H-indazolyl group Chemical group 0.000 description 1
- CWWAPMOEVNJEEL-UHFFFAOYSA-N 2,3-dimethyl-5h-pyrrolo[2,3-b]pyrazine Chemical compound N1=C(C)C(C)=NC2=C1NC=C2 CWWAPMOEVNJEEL-UHFFFAOYSA-N 0.000 description 1
- LSEAAPGIZCDEEH-UHFFFAOYSA-N 2,6-dichloropyrazine Chemical compound ClC1=CN=CC(Cl)=N1 LSEAAPGIZCDEEH-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- QDKQXFSDXRWWPB-LBPRGKRZSA-N 2-bromo-n-[(2s)-1-methoxypropan-2-yl]-6-(2-methoxy-6-propan-2-ylpyridin-3-yl)-4,5-dimethylpyridin-3-amine Chemical compound CC1=C(C)C(N[C@@H](C)COC)=C(Br)N=C1C1=CC=C(C(C)C)N=C1OC QDKQXFSDXRWWPB-LBPRGKRZSA-N 0.000 description 1
- OQXPRNLEKVAZDJ-NSHDSACASA-N 2-bromo-n-[(2s)-1-methoxypropan-2-yl]-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-5-methylpyridin-3-amine Chemical compound N1=C(Br)C(N[C@@H](C)COC)=CC(C)=C1C1=CC=C(OC(F)(F)F)C=C1OC OQXPRNLEKVAZDJ-NSHDSACASA-N 0.000 description 1
- YKHQFTANTNMYPP-UHFFFAOYSA-N 2-bromopyridin-3-ol Chemical compound OC1=CC=CN=C1Br YKHQFTANTNMYPP-UHFFFAOYSA-N 0.000 description 1
- VAVGOGHLNAJECD-UHFFFAOYSA-N 2-chloro-6-methoxypyridine Chemical compound COC1=CC=CC(Cl)=N1 VAVGOGHLNAJECD-UHFFFAOYSA-N 0.000 description 1
- IZLTZVZEBJLVDP-ZDUSSCGKSA-N 2-ethynyl-n-[(2s)-1-methoxypropan-2-yl]-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-5-methylpyridin-3-amine Chemical compound N1=C(C#C)C(N[C@@H](C)COC)=CC(C)=C1C1=CC=C(OC(F)(F)F)C=C1OC IZLTZVZEBJLVDP-ZDUSSCGKSA-N 0.000 description 1
- APOYTRAZFJURPB-UHFFFAOYSA-N 2-methoxy-n-(2-methoxyethyl)-n-(trifluoro-$l^{4}-sulfanyl)ethanamine Chemical compound COCCN(S(F)(F)F)CCOC APOYTRAZFJURPB-UHFFFAOYSA-N 0.000 description 1
- IWTFOFMTUOBLHG-UHFFFAOYSA-N 2-methoxypyridine Chemical compound COC1=CC=CC=N1 IWTFOFMTUOBLHG-UHFFFAOYSA-N 0.000 description 1
- BYVJZMGIFHMEFG-SXOMAYOGSA-N 2-morpholin-4-ylethyl (3s,4r)-3-(2-fluoroethoxy)-4-[5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-3,6-dimethylpyrrolo[3,2-b]pyridin-1-yl]pyrrolidine-1-carboxylate Chemical compound COC1=NC(C(C)C)=CC=C1C(C(=C1)C)=NC2=C1N([C@H]1[C@H](CN(C1)C(=O)OCCN1CCOCC1)OCCF)C=C2C BYVJZMGIFHMEFG-SXOMAYOGSA-N 0.000 description 1
- HLTDBMHJSBSAOM-UHFFFAOYSA-N 2-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CC=N1 HLTDBMHJSBSAOM-UHFFFAOYSA-N 0.000 description 1
- PFYPDUUXDADWKC-UHFFFAOYSA-N 2-propan-2-ylpyridine Chemical compound CC(C)C1=CC=CC=N1 PFYPDUUXDADWKC-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- SOSPMXMEOFGPIM-UHFFFAOYSA-N 3,5-dibromopyridine Chemical compound BrC1=CN=CC(Br)=C1 SOSPMXMEOFGPIM-UHFFFAOYSA-N 0.000 description 1
- ZJDPPWQFBXWULY-UHFFFAOYSA-N 3-(2,4-dimethoxyphenyl)-2-ethyl-7-pentan-3-ylfuro[2,3-b]pyrazine Chemical compound CCC=1N=C2C(C(CC)CC)=COC2=NC=1C1=CC=C(OC)C=C1OC ZJDPPWQFBXWULY-UHFFFAOYSA-N 0.000 description 1
- FHYWMOVEPQZGFO-UHFFFAOYSA-N 3-(3,6-dimethyl-1-propylpyrrolo[3,2-b]pyridin-5-yl)-n-ethyl-6-propan-2-ylpyridin-2-amine Chemical compound CC=1C=C2N(CCC)C=C(C)C2=NC=1C1=CC=C(C(C)C)N=C1NCC FHYWMOVEPQZGFO-UHFFFAOYSA-N 0.000 description 1
- RZIMNBKYMABSRW-UHFFFAOYSA-N 3-(3,7-dimethyl-5-propan-2-ylpyrrolo[2,3-b]pyrazin-2-yl)-6-propan-2-yl-1h-pyridin-2-one Chemical compound OC1=NC(C(C)C)=CC=C1C(C(=N1)C)=NC2=C1N(C(C)C)C=C2C RZIMNBKYMABSRW-UHFFFAOYSA-N 0.000 description 1
- XVDHMQDQXNESBM-UHFFFAOYSA-N 3-(5-bromo-3-methylpyridin-2-yl)-2-methoxy-6-propan-2-ylpyridine Chemical group COC1=NC(C(C)C)=CC=C1C1=NC=C(Br)C=C1C XVDHMQDQXNESBM-UHFFFAOYSA-N 0.000 description 1
- UWLJERQTLRORJN-UHFFFAOYSA-N 3-(trifluoromethoxy)phenol Chemical compound OC1=CC=CC(OC(F)(F)F)=C1 UWLJERQTLRORJN-UHFFFAOYSA-N 0.000 description 1
- YUIDPRYRVCCYEO-LBPRGKRZSA-N 3-bromo-1-[(2s)-1-methoxypropan-2-yl]-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-6-methylpyrrolo[3,2-b]pyridine Chemical compound CC=1C=C2N([C@@H](C)COC)C=C(Br)C2=NC=1C1=CC=C(OC(F)(F)F)C=C1OC YUIDPRYRVCCYEO-LBPRGKRZSA-N 0.000 description 1
- BURZJDSIJOMHQC-JTQLQIEISA-N 3-bromo-6-chloro-n-[(2s)-1-methoxypropan-2-yl]-5-(2-methoxy-6-propan-2-ylpyridin-3-yl)pyrazin-2-amine Chemical compound N1=C(Br)C(N[C@@H](C)COC)=NC(Cl)=C1C1=CC=C(C(C)C)N=C1OC BURZJDSIJOMHQC-JTQLQIEISA-N 0.000 description 1
- ROEPGHWJSYWGMZ-UHFFFAOYSA-N 3-bromo-6-ethyl-5-methylsulfonyl-1h-pyridin-2-one Chemical compound CCC1=NC(O)=C(Br)C=C1S(C)(=O)=O ROEPGHWJSYWGMZ-UHFFFAOYSA-N 0.000 description 1
- 125000005925 3-methylpentyloxy group Chemical group 0.000 description 1
- IXDLBVQJQLSNCF-UHFFFAOYSA-N 3-methylsulfonyl-1h-pyridin-2-one Chemical compound CS(=O)(=O)C1=CC=CNC1=O IXDLBVQJQLSNCF-UHFFFAOYSA-N 0.000 description 1
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical compound NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 description 1
- SJWHILBZPGQBJE-UHFFFAOYSA-N 4-ethylpyridin-2-amine Chemical compound CCC1=CC=NC(N)=C1 SJWHILBZPGQBJE-UHFFFAOYSA-N 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- UWWULBGQOSZTNU-UHFFFAOYSA-N 5-(2-ethyl-6-propan-2-ylpyridin-3-yl)-3,6-dimethyl-1-pentan-3-ylpyrrolo[3,2-b]pyridine Chemical compound CC=1C=C2N(C(CC)CC)C=C(C)C2=NC=1C1=CC=C(C(C)C)N=C1CC UWWULBGQOSZTNU-UHFFFAOYSA-N 0.000 description 1
- GHAINVFSRSEKTM-UHFFFAOYSA-N 5-(3,6-dimethyl-1-pentan-3-ylpyrrolo[3,2-b]pyridin-5-yl)-n,4-diethyl-n-methylpyridin-2-amine Chemical compound CC=1C=C2N(C(CC)CC)C=C(C)C2=NC=1C1=CN=C(N(C)CC)C=C1CC GHAINVFSRSEKTM-UHFFFAOYSA-N 0.000 description 1
- ODQZETYAUCYANV-INIZCTEOSA-N 5-(6-cyclopropyl-2-ethylpyridin-3-yl)-1-[(2s)-1-methoxypropan-2-yl]-3,6-dimethylpyrrolo[3,2-b]pyridine Chemical compound C=1C=C(C=2C(=CC=3N([C@@H](C)COC)C=C(C)C=3N=2)C)C(CC)=NC=1C1CC1 ODQZETYAUCYANV-INIZCTEOSA-N 0.000 description 1
- FCCGIKZKBIBAQS-MRXNPFEDSA-N 5-[(2r)-1-methoxybutan-2-yl]-2-(2-methoxy-6-propan-2-ylpyridin-3-yl)-3,7-dimethylpyrrolo[2,3-b]pyrazine Chemical compound CC=1N=C2N([C@@H](COC)CC)C=C(C)C2=NC=1C1=CC=C(C(C)C)N=C1OC FCCGIKZKBIBAQS-MRXNPFEDSA-N 0.000 description 1
- VOUZMOZWFCOPDS-SFHVURJKSA-N 5-[2-methoxy-4-(trifluoromethoxy)phenyl]-3,6-dimethyl-1-[(2s)-1-pyrrolidin-1-ylbutan-2-yl]pyrrolo[3,2-b]pyridine Chemical compound C([C@H](CC)N1C2=CC(C)=C(N=C2C(C)=C1)C=1C(=CC(OC(F)(F)F)=CC=1)OC)N1CCCC1 VOUZMOZWFCOPDS-SFHVURJKSA-N 0.000 description 1
- YAVKJNIMFGZBSY-UHFFFAOYSA-N 5-bromo-3,4-dimethylpyridin-2-amine Chemical compound CC1=C(C)C(N)=NC=C1Br YAVKJNIMFGZBSY-UHFFFAOYSA-N 0.000 description 1
- LAGLBZHHFADKIZ-UHFFFAOYSA-N 5-bromo-4-methoxy-n,n-dimethylpyridin-2-amine Chemical compound COC1=CC(N(C)C)=NC=C1Br LAGLBZHHFADKIZ-UHFFFAOYSA-N 0.000 description 1
- AZLVTLVOHJNYBL-UHFFFAOYSA-N 5-bromo-6-methyl-n-(3-methylbutyl)pyrazin-2-amine Chemical compound CC(C)CCNC1=CN=C(Br)C(C)=N1 AZLVTLVOHJNYBL-UHFFFAOYSA-N 0.000 description 1
- CSLMWTWXYFMOFH-LLVKDONJSA-N 5-bromo-n-[(2r)-1-[tert-butyl(dimethyl)silyl]oxypropan-2-yl]pyridin-3-amine Chemical compound CC(C)(C)[Si](C)(C)OC[C@@H](C)NC1=CN=CC(Br)=C1 CSLMWTWXYFMOFH-LLVKDONJSA-N 0.000 description 1
- SNKCOEGBSQBQME-UHFFFAOYSA-N 6-chloro-n-(3-methylbutyl)pyrazin-2-amine Chemical compound CC(C)CCNC1=CN=CC(Cl)=N1 SNKCOEGBSQBQME-UHFFFAOYSA-N 0.000 description 1
- MPVOWXAENXHCAP-NSHDSACASA-N 6-chloro-n-[(2s)-1-methoxypropan-2-yl]-5-(2-methoxy-6-propan-2-ylpyridin-3-yl)pyrazin-2-amine Chemical compound ClC1=NC(N[C@@H](C)COC)=CN=C1C1=CC=C(C(C)C)N=C1OC MPVOWXAENXHCAP-NSHDSACASA-N 0.000 description 1
- HGXXSKFMSMTAJE-LURJTMIESA-N 6-chloro-n-[(2s)-1-methoxypropan-2-yl]pyrazin-2-amine Chemical compound COC[C@H](C)NC1=CN=CC(Cl)=N1 HGXXSKFMSMTAJE-LURJTMIESA-N 0.000 description 1
- PTDQNSILPABWCA-HNNXBMFYSA-N 6-ethyl-2-methoxy-5-[1-[(2s)-1-methoxypropan-2-yl]-3,6-dimethylpyrrolo[3,2-b]pyridin-5-yl]-n-methylpyridine-3-carboxamide Chemical compound CCC1=NC(OC)=C(C(=O)NC)C=C1C(C(=C1)C)=NC2=C1N([C@@H](C)COC)C=C2C PTDQNSILPABWCA-HNNXBMFYSA-N 0.000 description 1
- JMFRWFPPCICJCQ-UHFFFAOYSA-N 6-methyl-1h-pyrrolo[3,2-b]pyridine Chemical compound CC1=CN=C2C=CNC2=C1 JMFRWFPPCICJCQ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 229940110385 Benzodiazepine receptor antagonist Drugs 0.000 description 1
- 241000143518 Bicyclus Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- UJZPNMGVHOEGOJ-FQEVSTJZSA-N C(C)(C)(C)[SiH2]OC([C@H](CC)NC=1C=NC(=C(C1)C)C1=C(C=C(C=C1)OC(F)(F)F)OC)(C)C Chemical compound C(C)(C)(C)[SiH2]OC([C@H](CC)NC=1C=NC(=C(C1)C)C1=C(C=C(C=C1)OC(F)(F)F)OC)(C)C UJZPNMGVHOEGOJ-FQEVSTJZSA-N 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 101000957724 Catostomus commersonii Corticoliberin-1 Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- YIIMEMSDCNDGTB-UHFFFAOYSA-N Dimethylcarbamoyl chloride Chemical compound CN(C)C(Cl)=O YIIMEMSDCNDGTB-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 description 1
- 206010015549 Euthyroid sick syndrome Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 102100034223 Golgi apparatus protein 1 Human genes 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 101100449731 Homo sapiens GLG1 gene Proteins 0.000 description 1
- 101100026648 Homo sapiens NAP1L3 gene Proteins 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
- 101100450563 Mus musculus Serpind1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- LJWZSXDLNMOUIP-UHFFFAOYSA-N N1C=CN=C2N=CC=C21 Chemical class N1C=CN=C2N=CC=C21 LJWZSXDLNMOUIP-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 101100028920 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cfp gene Proteins 0.000 description 1
- 102100022398 Nucleosome assembly protein 1-like 3 Human genes 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 208000008939 Pneumonic Pasteurellosis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010054048 Postoperative ileus Diseases 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101100439271 Schizosaccharomyces pombe (strain 972 / ATCC 24843) cfr1 gene Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- MCRWZBYTLVCCJJ-DKALBXGISA-N [(1s,3r)-3-[[(3s,4s)-3-methoxyoxan-4-yl]amino]-1-propan-2-ylcyclopentyl]-[(1s,4s)-5-[6-(trifluoromethyl)pyrimidin-4-yl]-2,5-diazabicyclo[2.2.1]heptan-2-yl]methanone Chemical compound C([C@]1(N(C[C@]2([H])C1)C(=O)[C@@]1(C[C@@H](CC1)N[C@@H]1[C@@H](COCC1)OC)C(C)C)[H])N2C1=CC(C(F)(F)F)=NC=N1 MCRWZBYTLVCCJJ-DKALBXGISA-N 0.000 description 1
- VHOHEIRLXFSQPZ-IBGZPJMESA-N [(2s)-2-[5-[2-methoxy-4-(trifluoromethoxy)phenyl]-3,6-dimethylpyrrolo[3,2-b]pyridin-1-yl]butyl] n-cyclopentylcarbamate Chemical compound C([C@H](CC)N1C2=CC(C)=C(N=C2C(C)=C1)C=1C(=CC(OC(F)(F)F)=CC=1)OC)OC(=O)NC1CCCC1 VHOHEIRLXFSQPZ-IBGZPJMESA-N 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- BBAWTPDTGRXPDG-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyridine Chemical compound C1=CC=C2SC=NC2=N1 BBAWTPDTGRXPDG-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- CUJRVFIICFDLGR-UHFFFAOYSA-N acetylacetonate Chemical compound CC(=O)[CH-]C(C)=O CUJRVFIICFDLGR-UHFFFAOYSA-N 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 239000000749 benzodiazepine receptor blocking agent Substances 0.000 description 1
- 239000000755 benzodiazepine receptor inverse stimulating agent Substances 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000005512 benztetrazolyl group Chemical group 0.000 description 1
- UQUSRBUOCMCVJA-IZLXSDGUSA-N benzyl (3r,4s)-3-[[2-bromo-6-(2-methoxy-6-propan-2-ylpyridin-3-yl)-5-methylpyridin-3-yl]amino]-4-[tert-butyl(dimethyl)silyl]oxypyrrolidine-1-carboxylate Chemical compound COC1=NC(C(C)C)=CC=C1C(C(=C1)C)=NC(Br)=C1N[C@H]1[C@@H](O[Si](C)(C)C(C)(C)C)CN(C(=O)OCC=2C=CC=CC=2)C1 UQUSRBUOCMCVJA-IZLXSDGUSA-N 0.000 description 1
- GDZALQBWTUKTQY-FTJBHMTQSA-N benzyl (3s,4r)-3-hydroxy-4-[5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-3,6-dimethylpyrrolo[3,2-b]pyridin-1-yl]pyrrolidine-1-carboxylate Chemical compound COC1=NC(C(C)C)=CC=C1C(C(=C1)C)=NC2=C1N([C@H]1[C@H](CN(C1)C(=O)OCC=1C=CC=CC=1)O)C=C2C GDZALQBWTUKTQY-FTJBHMTQSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- VALPXRNQZYGXPS-UHFFFAOYSA-N benzyl pyrrolidine-1-carboxylate Chemical compound C1CCCN1C(=O)OCC1=CC=CC=C1 VALPXRNQZYGXPS-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- FNXLCIKXHOPCKH-UHFFFAOYSA-N bromamine Chemical compound BrN FNXLCIKXHOPCKH-UHFFFAOYSA-N 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 108010050742 corticotropin releasing hormone (9-41) Proteins 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 108010011222 cyclo(Arg-Pro) Proteins 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 208000026725 cyclothymic disease Diseases 0.000 description 1
- VRLDVERQJMEPIF-UHFFFAOYSA-N dbdmh Chemical compound CC1(C)N(Br)C(=O)N(Br)C1=O VRLDVERQJMEPIF-UHFFFAOYSA-N 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- CPELXLSAUQHCOX-DYCDLGHISA-N deuterium bromide Chemical compound [2H]Br CPELXLSAUQHCOX-DYCDLGHISA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- IRUNKQSGDBYUDC-UHFFFAOYSA-N diethoxymethyl acetate Chemical compound CCOC(OCC)OC(C)=O IRUNKQSGDBYUDC-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 229940117360 ethyl pyruvate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- XEZPQQXHOCEWLB-UHFFFAOYSA-N furo[2,3-b]pyrazine Chemical class C1=CN=C2OC=CC2=N1 XEZPQQXHOCEWLB-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 125000004995 haloalkylthio group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004926 indolenyl group Chemical group 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- LZKLAOYSENRNKR-LNTINUHCSA-N iron;(z)-4-oxoniumylidenepent-2-en-2-olate Chemical compound [Fe].C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O LZKLAOYSENRNKR-LNTINUHCSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- QJQYPZZUKLQGGT-UHFFFAOYSA-N methyl hypobromite Chemical compound COBr QJQYPZZUKLQGGT-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- RLKHFSNWQCZBDC-UHFFFAOYSA-N n-(benzenesulfonyl)-n-fluorobenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(F)S(=O)(=O)C1=CC=CC=C1 RLKHFSNWQCZBDC-UHFFFAOYSA-N 0.000 description 1
- IXFBHPJZQQHPJH-CYBMUJFWSA-N n-[(2r)-1-[tert-butyl(dimethyl)silyl]oxypropan-2-yl]-5-ethylpyridin-3-amine Chemical compound CCC1=CN=CC(N[C@H](C)CO[Si](C)(C)C(C)(C)C)=C1 IXFBHPJZQQHPJH-CYBMUJFWSA-N 0.000 description 1
- YYFKJEIYVOWIOS-ZDUSSCGKSA-N n-[(2s)-1-methoxypropan-2-yl]-6-(2-methoxy-6-propan-2-ylpyridin-3-yl)-4,5-dimethylpyridin-3-amine Chemical compound CC1=C(C)C(N[C@@H](C)COC)=CN=C1C1=CC=C(C(C)C)N=C1OC YYFKJEIYVOWIOS-ZDUSSCGKSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- ZSEMLLOWRYITFB-HNNXBMFYSA-N n-[[1-[(2s)-1-methoxypropan-2-yl]-5-(2-methoxy-6-propan-2-ylpyridin-3-yl)-6-methylpyrrolo[3,2-b]pyridin-3-yl]methylidene]hydroxylamine Chemical compound CC=1C=C2N([C@@H](C)COC)C=C(C=NO)C2=NC=1C1=CC=C(C(C)C)N=C1OC ZSEMLLOWRYITFB-HNNXBMFYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- STCMDMFTMKSBSV-UHFFFAOYSA-N n-methoxypropan-2-amine Chemical compound CONC(C)C STCMDMFTMKSBSV-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- QEEJLLNYQOBRRM-KSHGRFHLSA-N ovine crf Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CN=CN1 QEEJLLNYQOBRRM-KSHGRFHLSA-N 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- QNNHQVPFZIFNFK-UHFFFAOYSA-N oxazolo[4,5-b]pyridine Chemical compound C1=CC=C2OC=NC2=N1 QNNHQVPFZIFNFK-UHFFFAOYSA-N 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- ZFLIKDUSUDBGCD-UHFFFAOYSA-N parabanic acid Chemical compound O=C1NC(=O)C(=O)N1 ZFLIKDUSUDBGCD-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- UMLDUMMLRZFROX-UHFFFAOYSA-N pyridin-2-ylboronic acid Chemical compound OB(O)C1=CC=CC=N1 UMLDUMMLRZFROX-UHFFFAOYSA-N 0.000 description 1
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- LYPGDCWPTHTUDO-UHFFFAOYSA-M sodium;methanesulfinate Chemical compound [Na+].CS([O-])=O LYPGDCWPTHTUDO-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 150000003413 spiro compounds Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- HXRSYWWXNCQKKC-QFIPXVFZSA-N tert-butyl-[(3S)-3-[5-[2-methoxy-4-(trifluoromethoxy)phenyl]-3,6-dimethylpyrrolo[3,2-b]pyridin-1-yl]-2-methylpentan-2-yl]oxysilane Chemical compound C(C)(C)(C)[SiH2]OC([C@H](CC)N1C=C(C2=NC(=C(C=C21)C)C2=C(C=C(C=C2)OC(F)(F)F)OC)C)(C)C HXRSYWWXNCQKKC-QFIPXVFZSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical group 0.000 description 1
- NYBWUHOMYZZKOR-UHFFFAOYSA-N tes-adt Chemical class C1=C2C(C#C[Si](CC)(CC)CC)=C(C=C3C(SC=C3)=C3)C3=C(C#C[Si](CC)(CC)CC)C2=CC2=C1SC=C2 NYBWUHOMYZZKOR-UHFFFAOYSA-N 0.000 description 1
- 125000006337 tetrafluoro ethyl group Chemical group 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 1
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
- 229940094989 trimethylsilane Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50041403P | 2003-09-05 | 2003-09-05 | |
| US60/500,414 | 2003-09-05 | ||
| PCT/US2004/028899 WO2005023806A2 (en) | 2003-09-05 | 2004-09-03 | Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2004270713A1 true AU2004270713A1 (en) | 2005-03-17 |
Family
ID=34272952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004270713A Abandoned AU2004270713A1 (en) | 2003-09-05 | 2004-09-03 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20050113379A1 (https=) |
| EP (1) | EP1680424A2 (https=) |
| JP (1) | JP2007504271A (https=) |
| KR (1) | KR20060088534A (https=) |
| CN (1) | CN1878773A (https=) |
| AP (1) | AP2006003559A0 (https=) |
| AR (1) | AR045582A1 (https=) |
| AU (1) | AU2004270713A1 (https=) |
| BR (1) | BRPI0414087A (https=) |
| CA (1) | CA2537829A1 (https=) |
| CR (1) | CR8274A (https=) |
| EA (1) | EA200600372A1 (https=) |
| EC (1) | ECSP066408A (https=) |
| IL (1) | IL174084A0 (https=) |
| MA (1) | MA28086A1 (https=) |
| NO (1) | NO20061180L (https=) |
| TW (1) | TW200530232A (https=) |
| WO (1) | WO2005023806A2 (https=) |
| ZA (1) | ZA200601978B (https=) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005028480A2 (en) * | 2003-09-03 | 2005-03-31 | Neurogen Corporation | 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds |
| US8273750B2 (en) | 2005-06-06 | 2012-09-25 | Takeda Pharmaceutical Company Limited | Organic compounds |
| RU2008110941A (ru) * | 2005-08-25 | 2009-09-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | ИНГИБИТОРЫ КИНАЗЫ p38 МАР И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| US8143285B2 (en) | 2005-09-06 | 2012-03-27 | Shionogi & Co., Ltd. | Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity |
| US7405302B2 (en) * | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| CN102775396B (zh) | 2005-11-08 | 2014-10-08 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的杂环调控剂 |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| EP1961754A4 (en) | 2005-12-15 | 2009-11-11 | Ono Pharmaceutical Co | BICYCLIC HETEROCYCLIC COMPOUND |
| TW200812588A (en) * | 2006-05-15 | 2008-03-16 | Neurogen Corp | CRF1 receptor ligands comprising heteroaryl fused bicycles |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| US9006258B2 (en) | 2006-12-05 | 2015-04-14 | Intra-Cellular Therapies, Inc. | Method of treating female sexual dysfunction with a PDE1 inhibitor |
| WO2008076446A1 (en) * | 2006-12-18 | 2008-06-26 | Coleman Peter R | Accelerated opiate dependence detoxification process |
| JP2010513370A (ja) * | 2006-12-19 | 2010-04-30 | エフ．ホフマン−ラ ロシュ アーゲー | ピラゾロ［３，４−ｄ］ピリミジンｐ３８ＭＡＰキナーゼインヒビター |
| WO2008083070A1 (en) * | 2006-12-29 | 2008-07-10 | Neurogen Corporation | Crf1 receptor ligands comprising fused bicyclic heteroaryl moieties |
| CN104447716A (zh) | 2007-05-09 | 2015-03-25 | 沃泰克斯药物股份有限公司 | Cftr调节剂 |
| ES2588238T3 (es) * | 2007-12-06 | 2016-10-31 | Intra-Cellular Therapies, Inc. | Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico |
| MX365732B (es) | 2007-12-07 | 2019-06-12 | Vertex Pharma | Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos. |
| EP3683218B1 (en) | 2007-12-07 | 2024-09-18 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
| NZ720282A (en) | 2008-02-28 | 2017-12-22 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
| ES2522346T3 (es) | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
| MX2011005936A (es) * | 2008-12-06 | 2011-12-16 | Intra Cellular Therapies Inc | Compuestos organicos. |
| AU2009322904A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP5989993B2 (ja) | 2008-12-06 | 2016-09-07 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| KR20110098732A (ko) | 2008-12-06 | 2011-09-01 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| WO2010065147A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CN102231953A (zh) | 2008-12-06 | 2011-11-02 | 细胞内治疗公司 | 有机化合物 |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| US8551996B2 (en) * | 2009-02-20 | 2013-10-08 | Emory University | Compounds, compositions, methods of synthesis, and methods of treatment |
| US9468637B2 (en) | 2009-05-13 | 2016-10-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2011092290A1 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| EP2531490B1 (en) | 2010-02-02 | 2014-10-15 | Novartis AG | Cyclohexyl amide derivatives as crf receptor antagonists |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| JP2013523833A (ja) | 2010-04-07 | 2013-06-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与 |
| WO2011153135A1 (en) | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US9434730B2 (en) | 2010-05-31 | 2016-09-06 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
| US9763948B2 (en) | 2010-05-31 | 2017-09-19 | Intra-Cellular Therapies, Inc. | PDE1 inhibitory compounds and methods |
| TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
| RU2013120966A (ru) | 2010-10-08 | 2014-11-20 | Эббви Инк. | ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ |
| AR086554A1 (es) | 2011-05-27 | 2014-01-08 | Novartis Ag | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
| EP2717877B1 (en) | 2011-06-10 | 2017-11-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| NZ727015A (en) | 2012-01-25 | 2017-12-22 | Vertex Pharma | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| ES2644781T3 (es) * | 2012-03-06 | 2017-11-30 | Bayer Intellectual Property Gmbh | Azabiciclos sustituidos y su uso |
| JP2015525202A (ja) | 2012-05-03 | 2015-09-03 | ノバルティス アーゲー | グレリン受容体アゴニストとしての２，７−ジアザ−スピロ［４，５］デカ−７−イル誘導体のｌ−リンゴ酸塩およびその結晶形態 |
| US9801882B2 (en) | 2013-02-17 | 2017-10-31 | Intra-Cellular Therapies, Inc. | Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases |
| US9545406B2 (en) | 2013-03-15 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Method of treating a CNS injury with a PDE1 inhibitor |
| CA2906640C (en) | 2013-03-15 | 2021-07-20 | Intra-Cellular Therapies, Inc. | Substituted imidazo-[1,2-a]pyrazolo[4.3-e]pyrimidin-4[5h]-one compounds and pharmaceutical compositions and use therof as pde1 inhibitors |
| KR102529049B1 (ko) | 2013-08-14 | 2023-05-08 | 노파르티스 아게 | 암의 치료를 위한 조합 요법 |
| AU2014349010C1 (en) | 2013-11-12 | 2020-08-06 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases |
| EP3102576B8 (en) | 2014-02-03 | 2019-06-19 | Vitae Pharmaceuticals, LLC | Dihydropyrrolopyridine inhibitors of ror-gamma |
| EP2940022B1 (en) * | 2014-04-30 | 2020-09-02 | Masarykova Univerzita | Furopyridines as inhibitors of protein kinases |
| WO2015196186A1 (en) | 2014-06-20 | 2015-12-23 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2016022893A1 (en) | 2014-08-07 | 2016-02-11 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
| BR112017005533B1 (pt) | 2014-09-17 | 2023-10-10 | Intra-Cellular Therapies, Inc | Compostos inibidores de fosfodiesterase 1 (pde1), composição farmacêutica que compreende os ditos compostos e usos dos mesmos no tratamento de uma doença, distúrbio, e/ou lesão do snc e no tratamento e/ou na profilaxia de uma doença, distúrbio e/ou lesão do snp |
| PT3207043T (pt) | 2014-10-14 | 2019-03-25 | Vitae Pharmaceuticals Llc | Inibidores de di-hidropirrolopiridina de ror-gama |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| RU2691136C2 (ru) | 2014-11-18 | 2019-06-11 | Вертекс Фармасьютикалз Инкорпорейтед | Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии |
| TW201625635A (zh) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物 |
| WO2017024018A1 (en) | 2015-08-05 | 2017-02-09 | Vitae Pharmaceuticals, Inc. | Modulators of ror-gamma |
| US11008340B2 (en) | 2015-11-20 | 2021-05-18 | Vitae Pharmaceuticals, Llc | Modulators of ROR-gamma |
| TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| EP3436083A4 (en) | 2016-03-28 | 2019-11-27 | Intra-Cellular Therapies, Inc. | NOVEL COMPOSITIONS AND METHOD |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| EP3510029B1 (en) * | 2016-09-07 | 2025-11-05 | The Regents of The University of California | Allosteric corticotropin-releasing factor receptor 1 (crfr1) antagonists that decrease p-tau and improve cognition |
| WO2018049417A1 (en) | 2016-09-12 | 2018-03-15 | Intra-Cellular Therapies, Inc. | Novel uses |
| JP2020528904A (ja) | 2017-07-24 | 2020-10-01 | ヴァイティー ファーマシューティカルズ，エルエルシー | ＲＯＲγの阻害剤 |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| JP7401442B2 (ja) | 2018-01-31 | 2023-12-19 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規使用 |
| CN110437846B (zh) * | 2019-08-30 | 2022-02-25 | 陕西师范大学 | 含炔键的氟取代苯并噁唑液晶化合物及其制备方法 |
| EP4025202A4 (en) | 2019-09-03 | 2023-08-02 | Intra-Cellular Therapies, Inc. | NOVEL CONNECTIONS |
| KR20220140515A (ko) | 2020-01-13 | 2022-10-18 | 버지 애널리틱스, 인크. | 치환된 피라졸로-피리미딘 및 그의 용도 |
| US12364695B2 (en) | 2020-06-02 | 2025-07-22 | Intra-Cellular Therapies, Inc. | Methods of treating inflammatory disease |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2153494C2 (ru) * | 1993-10-12 | 2000-07-27 | Дзе Дюпон Мерк Фармасьютикал Компани | 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция |
| US6020492A (en) * | 1995-05-12 | 2000-02-01 | Neurogen Corporation | Deazapurine derivatives; a new class of CRF1 specific ligands |
| JP3964478B2 (ja) * | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
| IL127566A0 (en) * | 1996-08-28 | 1999-10-28 | Pfizer | Substituted 6,5-hetero- bicyclic derivatives |
| JP2002510687A (ja) * | 1998-04-02 | 2002-04-09 | ニューロゲン コーポレイション | アミノアルキル置換ピロロ［２，３−ｂ］ピリジンおよびピロロ［２，３−ｄ］ピリミジン誘導体：ｃｒｆ１レセプタのモジュレータ |
| WO2002000623A2 (en) * | 2000-06-26 | 2002-01-03 | Neurogen Corporation | Aryl fused substituted 4-oxy-pyridines |
| DE10229777A1 (de) * | 2002-07-03 | 2004-01-29 | Bayer Ag | Indolin-Phenylsulfonamid-Derivate |
| EP1620095A4 (en) * | 2003-04-24 | 2009-04-01 | Merck & Co Inc | HEMMER OF ACT ACTIVITY |
-
2004
- 2004-09-03 US US10/933,834 patent/US20050113379A1/en not_active Abandoned
- 2004-09-03 AP AP2006003559A patent/AP2006003559A0/xx unknown
- 2004-09-03 CN CNA2004800327037A patent/CN1878773A/zh active Pending
- 2004-09-03 KR KR1020067004564A patent/KR20060088534A/ko not_active Withdrawn
- 2004-09-03 EA EA200600372A patent/EA200600372A1/ru unknown
- 2004-09-03 WO PCT/US2004/028899 patent/WO2005023806A2/en not_active Ceased
- 2004-09-03 AU AU2004270713A patent/AU2004270713A1/en not_active Abandoned
- 2004-09-03 CA CA002537829A patent/CA2537829A1/en not_active Abandoned
- 2004-09-03 ZA ZA200601978A patent/ZA200601978B/en unknown
- 2004-09-03 BR BRPI0414087-7A patent/BRPI0414087A/pt not_active IP Right Cessation
- 2004-09-03 EP EP04788585A patent/EP1680424A2/en not_active Withdrawn
- 2004-09-03 JP JP2006526210A patent/JP2007504271A/ja active Pending
- 2004-09-03 AR ARP040103174A patent/AR045582A1/es unknown
- 2004-09-06 TW TW093126841A patent/TW200530232A/zh unknown
-
2006
- 2006-03-02 IL IL174084A patent/IL174084A0/en unknown
- 2006-03-03 CR CR8274A patent/CR8274A/es unknown
- 2006-03-03 EC EC2006006408A patent/ECSP066408A/es unknown
- 2006-03-14 NO NO20061180A patent/NO20061180L/no not_active Application Discontinuation
- 2006-03-24 US US11/389,646 patent/US20060199823A1/en not_active Abandoned
- 2006-04-05 MA MA28916A patent/MA28086A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20060088534A (ko) | 2006-08-04 |
| JP2007504271A (ja) | 2007-03-01 |
| AP2006003559A0 (en) | 2006-04-30 |
| AR045582A1 (es) | 2005-11-02 |
| CR8274A (es) | 2008-06-10 |
| EP1680424A2 (en) | 2006-07-19 |
| TW200530232A (en) | 2005-09-16 |
| ZA200601978B (en) | 2007-05-30 |
| MA28086A1 (fr) | 2006-08-01 |
| WO2005023806A3 (en) | 2005-06-02 |
| CA2537829A1 (en) | 2005-03-17 |
| US20060199823A1 (en) | 2006-09-07 |
| NO20061180L (no) | 2006-03-31 |
| US20050113379A1 (en) | 2005-05-26 |
| ECSP066408A (es) | 2006-09-18 |
| WO2005023806A2 (en) | 2005-03-17 |
| BRPI0414087A (pt) | 2006-10-31 |
| IL174084A0 (en) | 2008-02-09 |
| EA200600372A1 (ru) | 2006-08-25 |
| CN1878773A (zh) | 2006-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2004270713A1 (en) | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | |
| CN112135824B (zh) | 作为免疫调节剂的杂环化合物 | |
| DE69824029T2 (de) | Bicyclische kinase inhibitoren | |
| CN100369912C (zh) | 用作gabaa受体配体的杂芳基取代的稠合双环杂芳基化合物 | |
| JP6689871B2 (ja) | Ｆｇｆｒ阻害剤としての二環式複素環 | |
| AU2004274403A1 (en) | 5-aryl-Pyrazolo(4,3-d)pyrimidines, pyridines, and pyrazines and related compounds | |
| EP1756104B1 (en) | Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands | |
| KR102073797B1 (ko) | 단백질 키나제 저해제로서의 아미노피리다지논 화합물 | |
| KR101481872B1 (ko) | Ｊａｋ의 억제제 | |
| KR20200139153A (ko) | A2a / a2b 억제제로서의 이미다조피리미딘 및 트리아졸로피리미딘 | |
| KR20210049090A (ko) | A2a/a2b 억제제로서 융합된 피라진 유도체 | |
| JP2019081786A (ja) | Ｔｒｋａキナーゼ阻害剤としてのｎ−ピロリジニル、ｎ’−ピラゾリル尿素、チオ尿素、グアニジン、およびシアノグアニジン化合物 | |
| JP2022542396A (ja) | Ｃｄ３８の阻害剤としてのヘテロ二環式アミド | |
| US20070129364A1 (en) | Pyrrolopyridine kinase inhibiting compounds | |
| EA036679B1 (ru) | Замещенные соединения тетрагидрохинолинона в качестве ингибиторов ретиноидных орфановых рецепторов гамма (ror) | |
| CN105209464A (zh) | P2x7调节剂 | |
| WO2006017443A2 (en) | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | |
| CA2713324A1 (en) | Pyrrolopyrazine kinase inhibitors | |
| WO2007133756A2 (en) | Crf1 receptor ligands comprising heteroaryl fused bicycles | |
| JP2016539990A (ja) | ブロモドメイン阻害薬 | |
| TW201623300A (zh) | 非典型蛋白質激酶ｃ之氮雜喹唑啉抑制劑 | |
| BR112015002262A2 (pt) | compostos, métodos para os tratamentos de uma condição inflamatória, artrite reumatóide, asma e distúrbio imunológico; composição farmacêutica, utilização do composto e invenção | |
| AU2021290208A1 (en) | Tricyclic compounds | |
| CN112912142B (zh) | 作为腺苷受体拮抗剂的5-氮杂吲唑衍生物 | |
| AU2004261591A1 (en) | Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |